BioLife Solutions (BLFS) 10-K 3 Mar 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 24, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-36362
Entity Registrant Name	BioLife Solutions, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 Monte Villa Parkway, Suite 310
Entity Address, City or Town	Bothell
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 784
Entity Common Stock, Shares Outstanding		47
Entity Central Index Key	0000834365
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor Information [Abstract]
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Bellevue, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 95,386	$ 27,896
Available-for-sale securities, current portion	9,198	16,288
Accounts receivable, trade, net of allowance for credit losses of $153 and $1,603 as of December 31, 2024 and December 31, 2023, respectively	9,168	7,898
Inventories	29,013	27,164
Prepaid expenses and other current assets	5,996	4,667
Current assets, discontinued operations	0	36,691
Total current assets	148,761	120,604
Assets held for rent, net	6,103	6,917
Property and equipment, net	6,084	5,689
Operating lease right-of-use assets, net	10,674	6,878
Long-term deposits and other assets	379	71
Available-for-sale securities, long term	4,628	548
Equity Investments	995	5,069
Intangible assets, net	9,559	11,996
Goodwill	212,304	212,304
Long-term assets, discontinued operations	0	42,638
Total assets	399,487	412,714
Current liabilities:
Accounts payable	3,573	2,270
Accrued expenses and other current liabilities	12,451	9,121
Sales taxes payable	4,256	4,400
Lease liabilities, operating, current portion	1,511	1,286
Debt, current portion	10,943	6,285
Current liabilities, discontinued operations	0	18,816
Total current liabilities	32,734	42,178
Lease liabilities, operating, long-term	12,723	8,695
Debt, long-term	4,997	17,561
Deferred tax liabilities	124	114
Long-term liabilities, discontinued operations	0	6,503
Total liabilities	50,578	75,051
Commitments and contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 46,906,765 and 45,167,225 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	47	45
Additional paid-in capital	683,939	652,880
Accumulated other comprehensive loss, net of taxes	24	(345)
Accumulated deficit	(335,101)	(314,917)
Total shareholders’ equity	348,909	337,663
Total liabilities and shareholders’ equity	$ 399,487	$ 412,714

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Allowance for doubtful accounts	$ 153	$ 1,603
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	46,906,765	45,167,225
Common stock, outstanding (in shares)	46,906,765	45,167,225
Series A Preferred Stock
Preferred stock, designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total product, service, and rental revenue	$ 82,254	$ 75,855	$ 76,239
Costs and operating expenses:
General and administrative	40,541	43,264	33,255
Sales and marketing	9,610	12,709	11,672
Research and development	7,912	12,073	8,671
Intangible asset amortization	2,737	3,520	3,990
Change in fair value of contingent consideration	0	(2,193)	(4,754)
Total operating expenses	89,383	99,295	82,162
Operating loss	(7,129)	(23,440)	(5,923)
Other (expense) income:
Interest expense, net	(719)	(1,449)	(284)
Other income	497	1,303	662
Change in fair value of investments	(4,074)	0	697
Gain on settlement of Global Cooling escrow	0	5,115	0
Total other (expense) income, net	(4,296)	4,969	1,075
(Loss) income from continuing operations before income tax benefit	(11,425)	(18,471)	(4,848)
Income tax benefit	38	24	5,236
(Loss) income from continuing operations	(11,387)	(18,447)	388
Discontinued operations:
Loss from discontinued operations before income tax expense	(8,665)	(49,362)	(139,979)
Income tax expense	(132)	(193)	(214)
Loss from discontinued operations	(8,797)	(49,555)	(140,193)
Net loss	$ (20,184)	$ (68,002)	$ (139,805)
Loss per share - Basic:
Loss per share - Basic: Continuing operations (in dollars per share)	$ (0.25)	$ (0.42)	$ 0.01
Loss per share - Basic: Discontinuing operations (in dollars per share)	(0.19)	(1.13)	(3.30)
Loss per share - Basic: Net Loss (in dollars per share)	(0.44)	(1.55)	(3.29)
Loss per share - Diluted:
Loss per share - Diluted: Continuing operations (in dollars per share)	(0.25)	(0.42)	0.01
Loss per share - Diluted: Discontinuing operations (in dollars per share)	(0.19)	(1.13)	(3.26)
Loss per share - Diluted: Net Loss (in dollars per share)	$ (0.44)	$ (1.55)	$ (3.25)
Weighted average shares used to compute net loss per share attributable to common shareholders:
Basic (in shares)	46,067,073	43,719,185	42,481,027
Diluted (in shares)	46,067,073	43,719,185	43,073,473
Product revenue
Total product, service, and rental revenue	$ 76,028	$ 68,968	$ 71,943
Costs and operating expenses:
Cost of revenue (exclusive of intangible assets amortization)	24,502	26,557	24,970
Service revenue
Total product, service, and rental revenue	160	349	73
Costs and operating expenses:
Cost of revenue (exclusive of intangible assets amortization)	52	0	0
Rental revenue
Total product, service, and rental revenue	6,066	6,538	4,223
Costs and operating expenses:
Cost of revenue (exclusive of intangible assets amortization)	$ 4,029	$ 3,365	$ 4,358

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (20,184)	$ (68,002)	$ (139,805)
Other comprehensive (loss) income - foreign currency translation adjustment, net of tax	0	278	(347)
Unrealized (loss) gain on available-for-sale securities, net of tax	(18)	56	(50)
Comprehensive loss	$ (20,202)	$ (67,668)	$ (140,202)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Series A Preferred Stock	Series A Preferred Stock Preferred Stock
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2021							0
Beginning balance at Dec. 31, 2021	$ 478,047	$ 42	$ 585,397	$ (282)	$ (107,110)		$ 0
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2021		41,817,503
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout (in shares)		64,130
Stock issued as consideration for SciSafe earnout	817		817
Fees incurred for registration filings	(131)		(131)
Stock-based compensation	25,334		25,334
Stock option exercises (in shares)		161,646
Stock option exercises	323		323
Stock issued – on vested RSAs (in shares)		788,952
Stock issued – on vested RSAs	0	$ 1	(1)
Other comprehensive income (loss)	(397)			(397)
Net loss	(139,805)				(139,805)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2022							0
Ending balance at Dec. 31, 2022	364,188	$ 43	611,739	(679)	(246,915)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2022		42,832,231
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout (in shares)		116,973
Stock issued as consideration for SciSafe earnout	2,263		2,263
Fees incurred for registration filings	(132)		(132)
Stock-based compensation	33,245		33,245
Stock option exercises (in shares)		239,043
Stock option exercises	507		507
Stock issued – on vested RSAs (in shares)		1,267,837
Stock issued – on vested RSAs	0	$ 1	(1)
Settlement of Global Cooling escrow (in shares)		(216,024)
Settlement of Global Cooling escrow	(5,115)		(5,115)
Common stock shares issued (in shares)		927,165
Common stock shares issued	10,375	$ 1	10,374
Other comprehensive income (loss)	334			334
Net loss	(68,002)				(68,002)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2023						0	0
Ending balance at Dec. 31, 2023	$ 337,663	$ 45	652,880	(345)	(314,917)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2023	45,167,225	45,167,225
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout	$ 0
Stock-based compensation	30,923		30,923
Stock option exercises (in shares)		90,250
Stock option exercises	202		202
Stock issued – on vested RSAs (in shares)		1,649,290
Stock issued – on vested RSAs	(64)	$ 2	(66)
Other comprehensive income (loss)	369			369
Net loss	(20,184)				(20,184)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2024						0	0
Ending balance at Dec. 31, 2024	$ 348,909	$ 47	$ 683,939	$ 24	$ (335,101)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2024	46,906,765	46,906,765

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (20,184)	$ (68,002)	$ (139,805)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Impairment of intangible assets	0	5,758	110,364
Impairment of long-lived assets	0	9,727	0
Gain on settlement of Global Cooling escrow	0	(5,115)	0
Depreciation	5,160	7,114	6,775
Amortization of intangible assets	3,501	5,181	9,697
Amortization of loan costs	0	13	18
Stock-based compensation	30,923	33,245	25,334
Non-cash lease expense	424	404	3,486
Deferred income tax benefit	(64)	(62)	(5,238)
Change in fair value of contingent consideration	0	(2,193)	(4,754)
Change in fair value of investments	4,074	0	(697)
Accretion of investments	(474)	(1,262)	(447)
Loss on disposal of assets held for rent, net	567	594	773
Loss on disposal of property and equipment, net	154	633	745
Net gain on disposal of subsidiaries	(15,877)	0	0
Other	0	0	166
Change in operating assets and liabilities
Accounts receivable, trade, net	(2,899)	15,351	(10,753)
Inventories	781	(8,552)	(6,559)
Prepaid expenses and other current assets	(2,407)	137	26
Accounts payable	26	(8,425)	414
Accrued expenses and other current liabilities	6,485	2,002	1,787
Sales taxes payable	(973)	1,311	1,526
Warranty liability	(528)	(454)	(1,086)
Other	(258)	97	(260)
Net cash provided by (used in) operating activities	8,431	(12,498)	(8,488)
Cash flows from investing activities
Purchases of property and equipment	(3,227)	(6,381)	(10,385)
Purchases of assets held for rent	(2,068)	(4,856)	(3,536)
Proceeds from sale of available-for-sale securities	3,518	3,469	420
Maturities of available-for-sale securities	18,400	52,700	8,500
Investment in available-for-sale securities	(18,415)	(27,095)	(53,116)
Purchases of intangible assets	(300)	0	0
Proceeds from sale of SciSafe and CBS	73,431	0	0
Payments on divestiture of Global Cooling	(13,039)	0	0
Net cash provided by (used in) investing activities	58,300	17,837	(58,117)
Cash flows from financing activities
Proceeds from term loan	0	0	20,000
Payments on term loan	(5,000)	(300)	(1,666)
Payments on equipment loans	(1,608)	(198)	(498)
Issuance of common stock	0	10,244	0
Fees paid related to issuance of common stock	0	0	(131)
Proceeds from exercise of common stock options	202	507	323
Proceeds from financed insurance premium	2,094	2,639	0
Payments on financed insurance premium	(2,397)	(2,365)	(1,375)
Other	(74)	64	(337)
Net cash (used in) provided by financing activities	(6,783)	10,591	16,316
Net increase in cash and cash equivalents	59,948	15,930	(50,289)
Cash and cash equivalents – beginning of period	35,438	19,473	69,870
Effects of currency translation on cash and cash equivalents	0	35	(108)
Cash and cash equivalents – end of period	95,386	35,438	19,473
Non-cash investing and financing activities
Assets acquired under operating leases	5,833	880	243
Assets acquired under finance leases	0	1,682	0
Purchase of property and equipment not yet paid	107	359	478
Unrealized (gain) loss on available-for-sale securities	(18)	(56)	50
Unrealized gain on currency translation	0	(12)	0
Stock issued as consideration for SciSafe earnout	0	2,263	817
Returned shares from settlement of Global Cooling escrow	0	(5,115)	0
Cash interest paid	$ 1,608	$ 1,927	$ 586

Organization and significant ac

Organization and significant accounting policies	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and significant accounting policies	Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction products and services including proprietary biopreservation media, automated thawing devices, and cloud-connected shipping containers. Our CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions by management affect the Company’s allowance for credit losses, the net realizable value of inventory, sales tax liabilities, valuation of market based stock awards, valuations related to investments and transaction activities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, certain accrued expenses, share-based compensation, and the provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation and consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Operations. The Consolidated Statements Of Comprehensive Loss, Consolidated Statements of Shareholders' Equity, and Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 3: Discontinued operations for additional details about the divestitures. All long-lived assets are maintained in the United States of America. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers , we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the observable and estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. During the year ended December 31, 2024, the Company recognized approximately $39 thousand of revenue that was included in the deferred revenue balance at the beginning of the year. The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, hPL media, evo ModPaks, and ThawSTAR products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statements of Operations. Service revenues are generated from various customer service agreements to provide warranty and other engineering services. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the year ended December 31, 2024. The Company generates revenue from the leasing of our evo cold chain systems to customers pursuant to rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases . All customers leasing shippers currently do so under rental arrangements for durations of one year or less, with each unit having the option to continue its rental arrangement on a month-to-month basis until returned to the Company beyond the initial rental period. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term. Total bioproduction products and services revenue for the years ended December 31, 2024, 2023, and 2022 were comprised of the following: Years Ended December 31, (In thousands, except percentages) 2024 2023 2022 Product revenue Cell processing $ 73,446 $ 65,772 $ 68,509 Evo and thaw 2,582 3,196 3,434 Service revenue Evo and thaw 160 349 73 Rental revenue Evo and thaw 6,066 6,538 4,223 Total revenue $ 82,254 $ 75,855 $ 76,239 There was no estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods as of December 31, 2024. The Company elected not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers . For additional information on the Company's revenues by geographic region, product line, and other customer concentration information, see Note 16: Segment, customer, and geographic information . Risks and uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates. (Loss) earnings per share from continuing operations Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. The following table presents computations of basic and diluted earnings per share: Year Ended December 31, (In thousands, except share and earnings per share data) 2024 2023 2022 Basic and diluted (loss) income from continuing operations per common share Numerator: (Loss) income from continuing operations $ (11,387) $ (18,447) $ 388 Denominator: Weighted-average common shares issued and outstanding - Basic 46,067,073 43,719,185 42,481,027 Effect of dilutive securities — — 592,446 Weighted-average common shares issued and outstanding - Diluted 46,067,073 43,719,185 43,073,473 Net (loss) income per share from continuing operations attributable to common shareholders Basic $ (0.25) $ (0.42) $ 0.01 Diluted $ (0.25) $ (0.42) $ 0.01 Anti-dilutive shares 1,283,885 647,348 — Cash and cash equivalents Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three months or less to be cash equivalents. We maintain cash balances that may exceed federally insured limits. We do not believe that this results in any significant credit risk. Available-for-sale securities Available-for-sale securities consist of U.S. government securities, corporate debt securities, and other debt securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale securities are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive (loss) income, net of any related tax effect. Realized gains and losses and other-than-temporary impairments on investments are included in other income. Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. The Company values thaw inventory at cost or, if lower, net realizable value, using the average costing method. All other inventory is valued at cost or, if lower, net realizable value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected revenue volume to cost of product revenue. The Company bases its estimates on expected product revenue volume, production capacity and expiration dates of raw materials, work in process, and finished products. A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During the year ended December 31, 2023, we assessed write-downs of approximately $3.4 million and recorded within the line item Inventories in the Company's Consolidated Balance Sheet. For additional information, see Note 6: Inventories . Work-in-process and finished products inventories consist of material, labor, outside testing costs and manufacturing overhead. Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 to 90 days) and are stated at the amount we expect to collect. We establish an allowance for credit losses based on our assessment of the collectability of specific customer accounts. Accounts considered uncollectible are charged against the established allowance. Accounts receivable are stated at principal amount, do not bear interest, and are generally unsecured. Accounts considered uncollectible are charged against the established allowance. Equity investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2024 and December 31, 2023, our investment in Series E Preferred Stock in PanTHERA CryoSolutions, Inc. (“PanTHERA”) was valued at $1.0 million. In November of 2020, the Company invested $1.0 million in Class E Preferred Shares in PanTHERA CryoSolutions, Inc. In conjunction with this investment, the Company executed a development and license agreement with PanTHERA under which the Company will make milestone development payments up to $2.0 million in the event that certain milestones are met in exchange for exclusive, perpetual, worldwide marketing and distribution rights to the technology for use in cell and gene therapy applications. As of December 31, 2024, the Company has paid $1.9 million in milestone development payments, with $0.9 million paid during the current year in accordance with the agreement. The Preferred Stock investments in PanTHERA are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar investments of the same issuer. As of December 31, 2024, management believes there are no indications of impairment or changes in fair value for the investment in PanTHERA. In November of 2020, the Company elected to convert a convertible note into Series A-1 Preferred Stock and invest an additional $1.0 million in Series A-2 Preferred Stock in iVexSol. The Preferred Stock investments in iVexSol were carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar investments of the same issuer. For the periods ending December 31, 2023 and 2022, the fair value of the Company's shares was $4.1 million. During the second quarter ending June 30, 2024, the Company received communications that triggered substantial doubt about a going concern for the investment. As of June 30, 2024, the Company determined that the fair value of its equity interest was less than its carrying amount, and no longer recoverable, triggering an impairment charge of $4.1 million, which represented the entirety of the value of the investment. Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of evo shippers and related components in production, shippers complete, ready to be deployed, and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Shippers are depreciated over a useful life of three years when in use by customers. Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. Carrying values are reviewed for recoverability at the asset grouping level to determine if the facts and circumstances suggest that a potential impairment may have occurred. If the sum of the expected future cash flows (undiscounted and before interest) from the use of the assets is less than the net book value of the asset, an impairment could exist and the amount of the impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. There were no impairment losses recognized during the years ended December 31, 2024, 2023, and 2022. Long-Lived Assets The Company reviews long-lived assets, including property and equipment, leased assets, and definite life intangible assets for impairment whenever events and changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest level for which identifiable independent cash flows are available ("asset group"). An impairment loss is recognized when the sum of the projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach or cost approach. Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a financing lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than twelve months. Over the lease term we use the effective interest rate method to account for the lease liability as lease payments are made and the ROU asset is amortized in a manner that results in straight-line expense recognition. The Company has elected the practical expedient and does not separate lease components from non-lease components for its leases. We elected to apply the practical expedient for short-term leases and accordingly do not apply lease recognition requirements for short-term leases with a duration less than twelve months. Instead, we recognize payments related to these arrangements in the Consolidated Statement of Operations as lease costs on a straight-line basis over the lease term. Warranty Our standard warranty terms typically cover one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not that the asset will not be realized. Our policy for interest and penalties is to recognize interest and penalties as a component of the provision for income taxes in the Consolidated Statement of Operations. We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2024, the Company has an unrecognized tax benefit of $1.2 million related to tax attributes being carried forward. The Company is generally subject to examination by U.S. federal and local income tax authorities for all tax years in which loss carryforward is available. Sales Taxes Payable The Company records sales tax collected from customers on a net basis, and therefore excludes it from total product, service and rental revenue as defined in ASC 606. Cash collected from customers is recorded in accrued expenses on the Company's Consolidated Balance Sheet and then remitted to the proper taxing authority. In addition, refer to Note 12: Commitments and contingencies for discussion regarding an estimated sales tax liability the Company recorded in relation to historical activity in certain states. As of December 31, 2024 and 2023, total interest expenses assessed on sales tax liabilities was $0.4 million and $0.4 million, respectively. As of December 31, 2022, no interest expenses had yet been assessed on sales tax liabilities. Advertising Advertising costs are expensed as incurred and totaled $0.9 million, $0.8 million, and $0.4 million for the years ended December 31, 2024, 2023, and 2022, respectively. Research and development Research and development costs are expensed as incurred. Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards, and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not amortized but is tested for impairment at least annually. The Company reviews goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate that the fair value of a reporting unit may be less than its carrying amount (a triggering event). The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test described in FASB ASC Topic 350, Intangibles – Goodwill and Other . The more likely than not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the quantitative goodwill impairment test is unnecessary and goodwill is considered to be unimpaired. However, if based on the qualitative assessment the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company will proceed with performing the quantitative goodwill impairment test. In performing the quantitative goodwill impairment test, the Company determines the fair value of its reporting unit and compares it to its carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company records an impairment loss equal to the difference. The Company operates as one reporting unit as of the goodwill impairment measurement date in the fourth quarter of 2024. As of the testing date and the period after that date through the issuance date of our financial statements, the Company has observed no indicators of potential goodwill impairment at any point during the period based on its required assessment. Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not found to be recoverable, it is written down to the estimated fair value of the asset based on the sum of the future discounted cash flows expected to result from the use and disposition of the asset. Recent accounting pronouncements Recently adopted accounting pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. We adopted this standard effective January 1, 2024 using a retrospective method. For additional information, refer to Note 16: Segment, customer, and geographic information . Recently issued accounting pronouncements not yet adopted In November 2024, FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses , which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements. In March 2024, the FASB issued ASU 2024-02, Codification Improvements to amend a variety of topics in the accounting codification by removing references to various FASB concepts statements. This accounting standard is effective for fiscal years beginning after December 15, 2024, and early adoption is permitted. ASU 2024-02 can be applied retrospectively to the beginning of the earliest comparative period presented in which the amendments were first applied or prospectively to all new transactions recognized on or after the date that the entity first applies the amendments. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires add

Correction of immaterial errors

Correction of immaterial errors	12 Months Ended
	Dec. 31, 2024
Accounting Changes and Error Corrections [Abstract]
Correction of immaterial errors	Correction of immaterial errors During the three months ended March 31, 2024, we determined that an error existed in our previously issued consolidated financial statements. Specifically, we identified that we had not properly accelerated stock compensation expense related to unvested shares of market-based awards of certain employees upon their termination during the fourth quarter of 2023. The error was evaluated under the U.S. SEC's Staff Accounting Bulletin ("SAB") Topic 1M, "Materiality," and SEC SAB Topic 1N, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in the Current Year Financial Statements" to determine the materiality of prior period misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not material to the previously issued consolidated financial statements. Although the error was not material to any period, we corrected the accompanying historical consolidated financial statements for the year ended December 31, 2023 to reflect the additional stock compensation expense incurred within each period for comparative purposes. As noted in our Basis of presentation and consolidation, the Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Operations. The Consolidated Statements Of Comprehensive Loss, Consolidated Statements of Shareholders' Equity, and Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. For purposes of comparability to the Company's presented Consolidated Balance Sheet and Consolidated Statements of Operations previously filed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 29, 2024, the Company is presenting the impact of the adjustments on a consolidated basis rather than presenting the divested companies as discontinued operations in the below tables. The following table represents the adjustments to our Consolidated Balance Sheet as of December 31, 2023 in accordance with ASC 250. The adjustments to our Consolidated Statement of Comprehensive Loss and Consolidated Statement of Shareholders’ Equity was limited to the adjustments outlined below. The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2023 was as follows: December 31, 2023 (In thousands) As reported Adjustment As corrected Additional paid-in-capital 651,305 1,575 652,880 Accumulated deficit (313,342) (1,575) (314,917) The effect of the adjustments to our Consolidated Statement of Operations for the year ended December 31, 2023 was as follows: December 31, 2023 (In thousands, except share and earnings per share data) As reported Adjustment As corrected General and administrative 55,725 1,414 57,139 Research and development 24,583 161 24,744 Total operating expenses 214,096 1,575 215,671 Operating loss (70,825) (1,575) (72,400) Loss from continuing operations before income tax benefit (66,258) (1,575) (67,833) Loss from continuing operations (66,427) (1,575) (68,002) Net loss per basic and diluted share from continuing operations (1.52) (0.04) (1.56) The effect of the adjustments to our Consolidated Statement of Cash Flows for the year ended December 31, 2023 was as follows: December 31, 2023 (In thousands, except share and earnings per share data) As reported Adjustment As corrected Net loss (66,427) (1,575) (68,002) Stock-based compensation 31,670 1,575 33,245

Discontinued operations

Discontinued operations	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued operations	Discontinued operations As announced in the second quarter of 2023, the Company, management, and our board of Directors (the "Board"), had determined that divesting Global Cooling and CBS (the "Freezer Business") would allow for the Company to optimize its product portfolio by focusing on its recurring higher margin revenue streams. Additionally, in November of 2024, the Company, management, and the Board determined the sale of SciSafe would further optimize the Company's product portfolio toward its proprietary high margin cell processing and other bioproduction products. The Company completed the sale of Global Cooling during the second quarter of 2024 and completed the sales of CBS and SciSafe during the fourth quarter of 2024. Accordingly, the results of these businesses are reported in the “ Loss from discontinued operations Divestiture of Global Cooling, Inc. On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock (the "GCI Divestiture") of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Global Cooling"), to GCI Holdings, an Ohio limited liability company ("Buyer") pursuant to a Stock Purchase Agreement, dated April 17, 2024, (the "Global Cooling Purchase Agreement"), by and between the Company and GCI Holdings. The Company analyzed the quantitative and qualitative factors relevant to the sale of Global Cooling and determined that the conditions for discontinued operations presentation were met during the second quarter of 2024. As a condition of the Global Cooling Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. The Company recognized a loss on disposal of Global Cooling, calculated as follows: (In thousands) Selling price: $1 $ — Cash to Global Cooling funded by Company (6,652) Costs to sell Global Cooling (1) (582) Negative selling price (7,234) Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities (3,589) Assumed liabilities: Accounts payable (2) 2,643 Assumed liabilities: Debt (3) 2,596 Less: Global Cooling carrying basis as of April 17, 2024 1,650 Less: Release of Global Cooling currency translation adjustment (13) Net loss on disposal $ (8,897) (1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties. (2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively. (3) As a closing condition, the Company repaid the balance of all obligations of Global Cooling under that certain promissory note payable by Global Cooling to a lender (the "Global Cooling Term Notes"). In connection with the Company’s entry into the Global Cooling Purchase Agreement, the Company implemented a RIF related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing approximately 11% of its full-time employees as of the date of the RIF). The Company’s Board approved the RIF on March 29, 2024, and all affected employees of Global Cooling were informed by April 18, 2024, following the execution of the Global Cooling Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration: (In thousands) Severance Stock Compensation Total RIF employee costs $ 291 $ 1,255 $ 1,546 Former Global Cooling employees — 1,925 1,925 Total employment related divestiture expenditures $ 291 $ 3,180 $ 3,471 As outlined in the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies. Prior to the GCI Divestiture, a lawsuit was filed by a previous customer related to Global Cooling's commercial freezer products seeking payment of up to $4.0 million for losses the customer claims to have incurred. As of December 31, 2024, the Company recorded a loss contingency under the discontinued operations of Global Cooing related to this product liability claim as outlined in the Global Cooling Purchase Agreement. During the fourth quarter of 2024, it became probable this loss would be settled within the next fiscal year. The product liability claim is subject to insurance recovery, which management believes is probable as enforceable under the Company's insurance policy, covering the entirety of the loss contingency aside from the Company's insurance deductibles. The Company estimates the legal expenses to be incurred will be immaterial. In addition, upon the closing of this transaction, the Company and Global Cooling entered into a transition services agreement ("GCI TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of this transaction. The GCI TSA has since expired pursuant to its terms on the stated expiration date. The Company has no other significant continuing involvement with Global Cooling. Divestiture of SciSafe, Inc. On November 12, 2024, the Company entered into a Stock Purchase Agreement (the "SciSafe Purchase Agreement"), by and among the Company, Subzero Purchaser Corp., a Delaware corporation ("SciSafe Buyer"), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company ("SciSafe Seller"), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company ("SciSafe"), for the sale by Sci Safe Seller of all of the issued and outstanding shares of common stock of SciSafe to SciSafe Buyer ("SciSafe Divestiture"). The Company analyzed the quantitative and qualitative factors relevant to the sale of SciSafe and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024. In connection with the closing of this transaction, the Company incurred $0.4 million in severance costs, paid the former stockholders of SciSafe $3.3 million in cash to waive all rights with respect to certain potential earn-out payments, and recognized $4.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with SciSafe upon the closing of this transaction. The Company recognized a gain on disposal of SciSafe, calculated as follows: (In thousands) Cash proceeds received from Buyer $ 71,291 Cash proceeds from escrow 483 Costs to sell (1) (506) Total proceeds 71,268 Less: SciSafe carrying basis as of November 12, 2024 42,507 Less: Release of SciSafe currency translation adjustment 622 Net gain on disposal $ 28,139 (1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million. In accordance with ASC 350, upon the disposal of SciSafe, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to SciSafe was based on the relative fair value of SciSafe to the fair value of the Company as SciSafe was fully integrated into the Company's one reportable segment. The fair value of SciSafe was determined based on the enterprise value per the SciSafe Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $11.3 million of goodwill was to be allocated to SciSafe upon its disposal. The allocated goodwill was included in the carrying basis of SciSafe presented in the above table. In addition, upon the closing of the transaction, the Company and SciSafe entered into a transition services agreement ("SciSafe TSA"), pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the closing of the transaction. The SciSafe Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the Closing Date. The Company has no other significant continuing involvement with SciSafe upon the expiration of its SciSafe TSA in April 2025 and other related covenants. In connection with the disposal of SciSafe, the Company remains liable and responsible for the full performance and observance of all of the provisions, covenants, and conditions in one of SciSafe's operating leases. In the case of a breach or violation of any provision of the lease by the buyer, the Company is deemed to be and shall constitute a default of the lease provisions. Simultaneously, the Company received indemnification pursuant any obligation owed by the Company under this operating lease. This indicates the Company undertakes the obligation to stand ready to perform over the term of the guarantee in the event of the specified triggering events noted above, or conditions, such as breach or default, occur. However, the non-contingent aspect of the guarantee enables the Company to recover any losses from the Buyer. As of December 31, 2024, the fair value of this guarantee is zero. The outstanding minimum lease payments equal approximately $2.3 million and the lease terminates in 2031. Divestiture of Custom Biogenics On November 14, 2024, the Company entered into a Stock Purchase Agreement (the "CBS Purchase Agreement"), by and among the Company, Standex International Corporation, a Delaware corporation, ("CBS Buyer") and Arctic Solutions, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (doing business as Custom Biogenic Systems, or ("CBS"), for the sale by the Company of all of the issued and outstanding shares of common stock of CBS. The Company analyzed the quantitative and qualitative factors relevant to the sale of CBS and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024. The Company recognized $2.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with CBS upon the closing of this transaction. The Company recognized a loss on disposal of CBS, calculated as follows: (In thousands) Cash proceeds received from Buyer $ 2,785 Cash proceeds from escrow 615 Net price adjustment (1) 179 Costs to sell (2) (148) Total proceeds 3,431 Less: CBS carrying basis as of November 14, 2024 6,796 Net loss on disposal $ (3,365) (1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the disposal. (2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million. In accordance with ASC 350, upon the disposal of CBS, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to CBS was based on the relative fair value of CBS to the fair value of the Company as CBS was fully integrated into the Company's one reportable segment. The fair value of CBS was determined based on the enterprise value per the CBS Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $1.1 million of goodwill was to be allocated to CBS upon its disposal. The allocated goodwill was included in the carrying basis of CBS presented in the above table. In addition, upon the closing of this transaction, the Company and CBS entered into a transition service agreement (the "CBS TSA"), pursuant to which the Company will provide certain transition services to CBS following the closing of the transaction. The CBS Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with CBS, soliciting its employees or interfering with its business relationships for two years after the closing of the CBS Transaction. The Company has no other significant continuing involvement with CBS upon the expiration of its CBS TSA and related covenants. Summarized financial data of discontinued operations The tables below summarize financial data of discontinued operations as of the year ended December 31, 2023 and for the years ended December 31, 2024, 2023, and 2022. Interest expenses directly associated with the debt of a disposed entity is reported in discontinued operations below. The table below summarizes the major classes of assets and liabilities of discontinued operations, which are summarized separately in the Consolidated Balance Sheets: December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Cash and cash equivalents $ 2,090 $ 5,102 $ 340 $ 7,532 Restricted cash — — 10 10 Accounts receivable, net 1,728 6,353 2,677 10,758 Inventories 11,248 — 5,044 16,292 Prepaid expenses and other current assets 303 895 901 2,099 Total current assets, discontinued operations 15,369 12,350 8,972 36,691 Assets held for rent, net — 796 — 796 Property and equipment, net 146 15,241 — 15,387 Operating lease right-of-use assets, net — 4,568 — 4,568 Financing lease right-of-use assets, net — 94 — 94 Long-term deposits and other assets 4 199 — 203 Intangible assets, net — 9,153 — 9,153 Goodwill — 11,333 1,104 12,437 Total assets, discontinued operations 15,519 53,734 10,076 79,329 Accounts payable 3,367 578 726 4,671 Accrued expenses and other current liabilities 1,156 1,300 573 3,029 Sales taxes payable 481 44 518 1,043 Warranty liability 7,507 — 131 7,638 Lease liabilities, operating, current portion 263 1,249 — 1,512 Lease liabilities, financing, current portion 22 74 280 376 Debt, current portion — 447 100 547 Total current liabilities, discontinued operations 12,796 3,692 2,328 18,816 Lease liabilities, operating, long-term 1,016 3,494 — 4,510 Lease liabilities, financing, long-term 11 27 1,130 1,168 Debt, long-term — 679 72 751 Deferred tax liabilities — — 74 74 Total liabilities, discontinued operations $ 13,823 $ 7,892 $ 3,604 $ 25,319 All divested entities had no remaining balances as of December 31, 2024. The key components of loss from discontinued operations were as follows: December 31, 2024 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 7,157 $ 18,440 $ 12,141 $ 37,738 Cost of revenue (8,389) (16,357) (10,600) (35,346) Operating expenses (9,418) (11,467) (4,967) (25,852) Intangible asset amortization — (764) — (764) Other expense, net (25) (183) (110) (318) (Loss) gain on disposal (8,897) 28,139 (3,365) 15,877 (Loss) income before income taxes (19,572) 17,808 (6,901) (8,665) Income tax expense (10) (122) — (132) (Loss) income from discontinued operations, net of income taxes $ (19,582) $ 17,686 $ (6,901) $ (8,797) December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 35,826 $ 18,014 $ 13,576 $ 67,416 Cost of revenue (36,682) (17,283) (12,632) (66,597) Operating expenses (20,162) (5,316) (7,153) (32,631) Intangible asset impairment charges (7,175) — (8,310) (15,485) Intangible asset amortization (131) (907) (623) (1,661) Other expense, net (90) (100) (214) (404) Loss before income taxes (28,414) (5,592) (15,356) (49,362) Income tax expense (4) (180) (9) (193) Loss from discontinued operations, net of income taxes $ (28,418) $ (5,772) $ (15,365) $ (49,555) December 31, 2022 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 47,915 $ 21,462 $ 16,142 $ 85,519 Cost of revenue (51,621) (15,060) (11,928) (78,609) Operating expenses (19,211) (5,697) (5,548) (30,456) Intangible asset impairment charges (110,364) — — (110,364) Intangible asset amortization (3,969) (907) (830) (5,706) Other expense, net (255) (84) (24) (363) Loss before income taxes (137,505) (286) (2,188) (139,979) Income tax expense (14) (191) (9) (214) Loss from discontinued operations, net of income taxes $ (137,519) $ (477) $ (2,197) $ (140,193) Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations: December 31, 2024 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ — $ 2,402 $ 4 $ 2,406 Amortization — 764 — 764 Stock-based compensation 4,191 6,410 3,790 14,391 Interest expense, net 42 50 114 206 Capital expenditures — 2,200 720 2,920 December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ 397 $ 2,636 $ 471 $ 3,504 Amortization 131 907 623 1,661 Stock-based compensation 4,734 2,759 2,503 9,996 Interest expense, net 131 13 219 363 Capital expenditures — 4,659 750 5,409 December 31, 2022 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ 616 $ 2,081 $ 488 $ 3,185 Amortization 3,969 907 830 5,706 Stock-based compensation 3,304 2,465 1,839 7,608 Interest expense, net 257 118 28 403 Capital expenditures — 6,790 812 7,602

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures , (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no remeasurements to fair value during the year ended December 31, 2024 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023, based on the three-tier fair value hierarchy: (In thousands) As of December 31, 2024 Level 1 Level 2 Total Assets: Cash equivalents: Money market accounts $ 89,119 — $ 89,119 Available-for-sale securities: U.S. government securities 1,494 — 1,494 Corporate debt securities 398 8,602 9,000 Other debt securities — 3,332 3,332 Total 91,011 11,934 102,945 As of December 31, 2023 Level 1 Level 2 Total Assets: Cash equivalents: Money market accounts $ 25,034 — $ 25,034 Available-for-sale securities: U.S. government securities 5,170 — 5,170 Corporate debt securities — 9,674 9,674 Other debt securities — 1,992 1,992 Total 30,204 11,666 41,870 There have been no transfers of assets or liabilities between the fair value measurement levels. We had no financial assets or liabilities that utilize Level 3 inputs of measurement as of December 31, 2024 and 2023. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs for the year ended December 31, 2023: Year Ended December 31, (In thousands) 2023 Balance at beginning of period $ 4,456 Change in fair value recognized in net loss from continuing operations (2,193) Payment of contingent consideration earned (2,263) Balance at end of period $ —

Investments

Investments	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: December 31, 2024 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 1,493 $ 1 $ — $ 1,494 Corporate debt securities 5,775 14 (1) 5,788 Other debt securities 1,912 4 — 1,916 Total short-term 9,180 19 (1) 9,198 Available-for-sale securities, long-term Corporate debt securities 3,210 4 (2) 3,212 Other debt securities 1,412 5 (1) 1,416 Total available-for-sale securities $ 13,802 $ 28 $ (4) $ 13,826 December 31, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,169 $ 1 $ — $ 5,170 Corporate debt securities 9,673 5 (4) 9,674 Other debt securities 1,443 1 — 1,444 Total short-term 16,285 7 (4) 16,288 Available-for-sale securities, long-term Other debt securities 545 3 — 548 Total available-for-sale securities $ 16,830 $ 10 $ (4) $ 16,836 The following table summarizes the contractual maturities of the short-term and long-term available-for-sale investments as of December 31, 2024: (In thousands) Amortized Estimated Due in one year or less $ 9,180 $ 9,198 Due after one year through five years 4,622 4,628 Total $ 13,802 $ 13,826 The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months: December 31, 2024 Less than 12 months Total (In thousands) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,091 $ (3) $ 2,091 $ (3) Other debt securities 1,030 (1) 1,030 (1) Total $ 3,121 $ (4) $ 3,121 $ (4) December 31, 2023 Less than 12 months Total (In thousands) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 5,871 $ (4) $ 5,871 $ (4) Other debt securities 906 (1) 906 (1) Total $ 6,777 $ (5) $ 6,777 $ (5) As of December 31, 2024 and 2023, all available-for-sale securities investments presented above with unrealized losses have been in an unrealized loss position for less than 12 months. As of December 31, 2024, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded. Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The non-marketable equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar investments of the same issuer. These securities included Series E Preferred Stock in PanTHERA CryoSolutions, Inc. with a fair value of $1.0 million as of December 31, 2024 and December 31, 2023. The Company also owned securities of Series A-1 and A-2 Preferred Stock in iVexSol, Inc "iVexSol". During the six months ended June 30, 2024, the Company received communications that triggered a going concern for the investment. As of June 30, 2024, the Company determined that the fair value of its equity interest was less than its carrying amount, and no longer recoverable, triggering an impairment charge of $4.1 million, which represented the entirety of the value of the investment. As of December 31, 2023, the carrying value of the iVexSol, Inc. securities was $4.1 million.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Raw materials $ 11,768 $ 14,668 Work in progress 4,082 3,475 Finished goods 13,163 9,021 Total $ 29,013 $ 27,164 During the year ended December 31, 2023, the Company recorded a $3.4 million inventory write-down for potentially unusable products. The products consisted of slow-moving inventory, product defects, and supplier defects in raw materials.

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases We have various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of four one one We did not have any financing lease arrangements as of December 31, 2024 and 2023. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2024 and 2023: 2024 2023 Weighted average discount rate - operating leases 6.4 % 4.5 % Weighted average remaining lease term in years - operating leases 6.1 7.1 The components of lease expense for the years ended December 31, 2024, 2023, and 2022 were as follows: Year Ended December 31, (In thousands) 2024 2023 2022 Operating lease costs $ 1,997 $ 1,630 $ 1,560 Short-term lease costs 59 260 280 Total operating lease costs 2,056 1,890 1,840 Variable lease costs 1,103 797 677 Total lease expense $ 3,159 $ 2,687 $ 2,517 Maturities of our lease liabilities as of December 31, 2024 are as follows: (In thousands) Operating Leases 2025 $ 2,351 2026 3,029 2027 2,583 2028 2,642 2029 2,724 Thereafter 3,946 Total lease payments 17,275 Less: interest (3,041) Total present value of lease liabilities $ 14,234
Leases	Leases We have various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of four one one We did not have any financing lease arrangements as of December 31, 2024 and 2023. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2024 and 2023: 2024 2023 Weighted average discount rate - operating leases 6.4 % 4.5 % Weighted average remaining lease term in years - operating leases 6.1 7.1 The components of lease expense for the years ended December 31, 2024, 2023, and 2022 were as follows: Year Ended December 31, (In thousands) 2024 2023 2022 Operating lease costs $ 1,997 $ 1,630 $ 1,560 Short-term lease costs 59 260 280 Total operating lease costs 2,056 1,890 1,840 Variable lease costs 1,103 797 677 Total lease expense $ 3,159 $ 2,687 $ 2,517 Maturities of our lease liabilities as of December 31, 2024 are as follows: (In thousands) Operating Leases 2025 $ 2,351 2026 3,029 2027 2,583 2028 2,642 2029 2,724 Thereafter 3,946 Total lease payments 17,275 Less: interest (3,041) Total present value of lease liabilities $ 14,234

Assets held for rent

Assets held for rent	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Assets held for rent	Assets held for rent Assets held for rent consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Shippers placed in service $ 9,505 $ 9,866 Accumulated depreciation (6,499) (5,600) Net 3,006 4,266 Shippers and related components in production 3,097 2,651 Total $ 6,103 $ 6,917 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $2.1 million, $2.9 million, and $2.8 million in depreciation expense related to assets held for rent during the years ended December 31, 2024, 2023, and 2022, respectively.

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment Property and equipment consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Property and equipment Leasehold improvements $ 3,527 $ 3,503 Furniture and computer equipment 306 596 Manufacturing and other equipment 4,073 3,340 Construction in-progress 2,478 2,513 Subtotal 10,384 9,952 Less: Accumulated depreciation (4,300) (4,263) Property and equipment, net $ 6,084 $ 5,689 Depreciation expense for property and equipment was $0.7 million, $0.8 million, and $0.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Accrued expenses and other curr

Accrued expenses and other current liabilities	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Accrued expenses $ 7,116 $ 6,620 Accrued taxes — 264 Accrued compensation 5,232 2,196 Deferred revenue, current 103 41 Total accrued expenses and other current liabilities $ 12,451 $ 9,121

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill (In thousands) Goodwill Original acquired goodwill as of December 31, 2023 (1) $ 224,741 Less: Goodwill allocated to SciSafe in divestiture (11,333) Less: Goodwill allocated to CBS in divestiture (1,104) Balance as of December 31, 2024 $ 212,304 (1) As discussed in Note 3: Discontinued operations, the Company allocated a portion of its goodwill to each disposed entity in accordance with ASC 350. The goodwill balance presented above as of December 31, 2023 represents the balance of the reporting unit before the effect of the divestitures. The goodwill presented in the Consolidated Balance Sheets as of December 31, 2024 and 2023 is on a continuing operations basis giving effect to the divestitures. Intangible assets Intangible assets, net consisted of the following as of December 31, 2024 and 2023: (In thousands, except weighted average useful life) December 31, 2024 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life Customer relationships $ 2,516 $ (2,508) $ 8 0.6 Tradenames 4,114 (1,799) 2,315 5.9 Technology - acquired 18,672 (11,436) 7,236 3.1 Non-compete agreements 90 (90) — 0.0 Total intangible assets $ 25,392 $ (15,833) $ 9,559 3.3 December 31, 2023 Intangible assets: Gross Carrying Value Accumulated Amortization (1) Net Carrying Value Weighted Average Useful Life Customer relationships $ 2,516 $ (2,495) $ 21 1.6 Tradenames 4,114 (1,389) 2,725 6.9 Technology - acquired 18,372 (9,122) 9,250 4.1 Non-compete agreements 90 (90) — 0.0 Total intangible assets $ 25,092 $ (13,096) $ 11,996 4.3 Amortization expense for finite-lived intangible assets was $2.7 million, $3.5 million, and $4.0 million for the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the Company expects to record the following amortization expense: (In thousands) For the Years Ending December 31, Estimated 2025 $ 2,807 2026 2,692 2027 1,938 2028 828 2029 530 Thereafter 764 Total $ 9,559

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the officer or upon the officer resigning for good reason. Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business. The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation except for as described below. Pending litigation items One lawsuit has been filed by a previous customer seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. Pursuant to the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies and if this previous customer was successful on such claim, then the Company would be responsible for indemnifying Global Cooling for any losses. This lawsuit does not currently have probable outcomes determined and we continue to defend vigorously against the claims made. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential loss incurred to be covered by insurance. Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31, 2024. Non-income related taxes Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2022, the Company determined that a sales tax liability related to the periods of 2019 through 2022 is probable. The estimated liability was determined to be approximately $4.3 million and $4.4 million as of December 31, 2024 and December 31, 2023, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period. Settlement of Global Cooling Escrow On May 3, 2021, the Company acquired GCI pursuant to an Agreement and Plan of Merger, dated as of March 19, 2021 (the “GCI Merger Agreement”). Pursuant to the GCI Merger Agreement, the aggregate consideration paid to former stockholders of GCI (collectively, the “GCI Stockholders”) was 6,646,870 newly issued shares of common stock (the “GCI Merger Consideration”) were provided with the requirement that the GCI Merger Consideration otherwise payable to GCI Stockholders were subject to reduction for indemnification obligations. Approximately 9% of the GCI Merger Consideration (the "GCI Escrow Shares") otherwise issuable to the GCI Stockholders were deposited into a segregated escrow account (the “GCI Escrow Account”) in accordance with an escrow agreement entered into in connection with the closing of the transactions contemplated by the GCI Merger Agreement (the “GCI Escrow Agreement”). Of the GCI Escrow Shares, an amount equal to 5% of the GCI Merger Consideration were considered general escrow shares (the “General Escrow Shares”). The General Escrow Shares were eligible to be held in escrow for a period of up to 18 months after the closing of the GCI acquisition as the sole and exclusive source of payment for any indemnification claims made by the Company. On September 28, 2022, BioLife asserted an indemnification claim pursuant to the GCI Merger Agreement. On June 5, 2023, the Company entered into a Settlement Agreement with the representatives of the GCI Stockholders, pursuant to which the parties agreed to release 65% of the General Escrow Shares, totaling 216,024 shares, to the Company from the GCI Escrow Account. These shares were returned to the Company and subsequently cancelled. As a result of the settlement, the Company recorded a $5.1 million gain recognizing the return of the shares during the second quarter of 2023.

Long-term debt

Long-term debt	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-term debt	Long-term debt Term Loan On September 20, 2022, the Company and certain of its subsidiaries entered into the Loan and Security Agreement, dated September 20, 2022, by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton,” and together with the Company, SAVSU, Arctic and SciSafe Parent, “Borrower”), as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Second Amendment”), and that certain Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024 (the “Third Amendment”, and the foregoing collectively, the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing were interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. The Company has begun its interest payments on the Term Loan as of June 2024. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1 million. As of December 31, 2024, the implied interest rate of the Term Loan is 8.9% and the implied value of the Term Loan is $15.9 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of December 31, 2024, the Company is in compliance with the covenants set forth in the Loan Agreement. On April 17, 2024, the Company entered into the Second Amendment by and among Bank and Borrower. Pursuant to the Second Amendment and subject to the conditions set forth therein, Bank consented to the GCI Divestiture and released its security interests in the assets of Global Cooling and the shares of common stock of Global Cooling arising under the Loan Agreement. In addition, effective as of the closing of the transaction, the Second Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Second Amendment also contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement. On November 11, 2024, the Company entered into the Third Amendment by and among Bank and Borrower. Pursuant to the Third Amendment and subject to the conditions set forth therein, Bank consented to the SciSafe Divestiture as required pursuant to the Loan Agreement. In addition, effective as of the closing of the SciSafe Divestiture, the Third Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date for any reason. The Third Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement. Long-term debt consisted of the following as of December 31, 2024 and 2023: December 31, (In thousands) Maturity Date Interest Rate 2024 2023 Global Cooling Term Notes (1) Various 4.0 % $ — $ 2,596 Term Loan (2) Jun-26 7.0 % 15,000 20,000 Insurance premium financing Various 8.3 % 975 1,348 Total debt, excluding unamortized debt issuance costs 15,975 23,944 Less: unamortized debt issuance costs (35) (98) Total debt 15,940 23,846 Less: current portion of debt (10,943) (6,285) Total long-term debt $ 4,997 $ 17,561 (1) The Company repaid the balance of all obligations of the Global Cooling Term Notes pursuant to the Global Cooling Purchase Agreement. (2) As of December 31, 2024, the Term Loan was secured by substantially all assets of BioLife, SAVSU, and Sexton, other than intellectual property. As of December 31, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2025 $ 10,943 2026 4,997 2027 — 2028 — 2029 — Thereafter — Total $ 15,940

Stock-based compensation

Stock-based compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation Stock compensation plans Our stock-based compensation programs are long-term retention programs that are intended to attract, retain, and provide incentives for talented employees, officers, and directors, and to align stockholder and employee interests. Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4 year period, and forfeitures recognized as incurred. We have the following stock-based compensation plans and programs: During 2013, we adopted the 2013 Performance Incentive Plan (the “2013 Plan”), which allowed us to grant options or restricted stock awards to all employees, including executive officers, outside consultants and non-employee directors. An aggregate of 3.1 million shares of common stock was initially reserved for issuance under the 2013 Plan. In May 2017, July 2020, June 2021, and June 2022, the shareholders approved an increase in the number of shares available for issuance to 4.1 million shares, 5.0 million shares, 6.5 million shares, and 8.5 million shares, respectively. As of April 25, 2023, the 2013 Plan expired as to future awards in accordance with its terms. As of December 31, 2024, there were outstanding options to purchase 127,000 shares of the Company’s common stock and approximately 0.5 million unvested restricted stock awards outstanding under the 2013 Plan. On July 21, 2023, our stockholders approved the 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). The 2023 Plan allows us to grant equity awards to employees, directors, and outside consultants. An aggregate of 4.2 million shares of common stock were initially reserved for issuance under the 2023 Plan, plus any shares subject to awards under the 2013 Plan that were outstanding as of July 21, 2023, and which are subsequently forfeited or lapsed and not issued under the 2013 Plan. As of December 31, 2024, there were approximately 1.4 million unvested restricted stock awards outstanding under the 2023 Plan. Issuance of shares When options are exercised, it is the Company’s policy to issue new shares. Stock option activity Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the year ended December 31, 2024 and 2023, and the status of service vesting-based stock options outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Shares Wtd. Avg. Outstanding as of beginning of year 217,250 $ 2.21 456,293 $ 2.17 Exercised (90,250) 2.23 (239,043) 2.12 Outstanding at end of year 127,000 $ 2.19 217,250 $ 2.21 Stock options exercisable at year end 127,000 $ 2.19 217,250 $ 2.21 We did not recognize stock compensation expense related to service-based options during the years ended December 31, 2024, 2023, and 2022. As of December 31, 2024, there was $3.0 million of aggregate intrinsic value of outstanding service vesting-based stock options, including $3.0 million of aggregate intrinsic value of exercisable service vesting-based stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the year and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on December 31, 2024. This amount will change based on the fair market value of the Company’s stock. Intrinsic value of service vesting-based awards exercised during the years ended December 31, 2024, 2023, and 2022 was $1.8 million, $3.9 million, and $4.1 million, respectively. There were no service based-vesting options granted during the years ended December 31, 2024, 2023, and 2022. The weighted average remaining contractual life of service vesting-based options outstanding and exercisable as of December 31, 2024 is 1.4 years. There were no unrecognized compensation costs for service vesting-based stock options as of December 31, 2024. The following table summarizes information about service vesting-based stock options outstanding as of December 31, 2024: Range of Exercise Prices Number Outstanding at Weighted Average Weighted Average Exercise $1.00 - 1.50 2,000 1.85 $ 1.49 $1.51 - 2.00 115,000 1.32 1.89 $2.51 - 8.60 10,000 2.92 5.69 127,000 1.45 $ 2.19 Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2024 and 2023, and the status of unvested service vesting-based restricted stock outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Grant Shares Wtd. Avg. Grant Outstanding as of beginning of year 2,312,898 $ 18.32 1,879,215 $ 28.94 Granted 484,886 20.65 1,907,101 13.12 Vested (1,323,729) 21.57 (1,237,221) 24.97 Forfeited (178,415) 17.09 (236,197) 25.88 Non-vested at year end 1,295,640 $ 16.00 2,312,898 $ 18.32 The aggregate fair value of the service vesting-based awards granted during the years ended December 31, 2024, 2023, and 2022 was $10.0 million, $25.0 million, and $34.7 million, respectively. The aggregate fair value of the service vesting-based awards that vested during the years ended December 31, 2024, 2023, and 2022 was $27.7 million, $20.5 million, and $12.6 million, respectively. On October 19, 2023, Michael Rice, the Chief Executive Officer at that time, announced his resignation from the company. In accordance with his separation agreement, all unvested stock grants, excluding the 99,038 market-based restricted stock units awarded to him January 3, 2023 and the 70,094 market-based restricted stock units awarded to him on February 24, 2022 by the Board, were accelerated and vested as of the date of his separation. The Company recognized stock compensation expense in connection with the acceleration of his unvested stock grants of $1.7 million, representing 150,155 shares. His market-based restricted stock awards will vest once the stated market condition term for each award occurs. We recognized stock compensation expense of $10.8 million, $15.7 million, and $13.6 million related to service vesting-based awards during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, there was $18.0 million in unrecognized compensation costs related to service vesting-based awards. We expect to recognize those costs over 2.6 years. Performance-based restricted stock On March 8, 2024, the Company granted 109,512 shares of performance-based stock to an executive in the form of restricted stock. The shares granted contain performance conditions based on Company metrics related to future performance. The performance-based award was structured to vest between 0% and 200% of the number of restricted shares granted to the recipient based on the achievement of certain financial metrics related to future performance. The grant date fair value of this award was $17.36 per share. During the fourth quarter of the year ended December 31, 2024, it was determined the probability of attainment of the performance condition increased to greater than 100% of shares granted. In accordance with ASC 718, we recognized a cumulative catch up in stock compensation expense of $0.4 million to reflect the increased probability the performance-based award would vest in excess of the shares originally granted. The fair value of this award is being expensed on a straight-line basis in accordance with the estimated quantity of shares expected to vest over the requisite service period ending on December 31, 2025. We recognized stock compensation expense of $1.2 million related to performance-based restricted stock awards for the year ended December 31, 2024. As of December 31, 2024, there was $1.5 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 1.0 year. Non-cash compensation costs are expensed over the period for which performance was measured. The aggregate fair value of the performance-based awards granted during the year ended December 31, 2024 was $1.9 million. No performance-based awards vested during the year ended December 31, 2024. No performance-based restricted stock awards were granted or vested during the years ended December 31, 2023 and 2022. Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the years ended December 31, 2024 and 2023 and the status of market-based restricted stock outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Grant Date Fair Shares Wtd. Avg. Grant Date Fair Outstanding as of beginning of year 509,166 $ 26.50 271,044 $ 30.64 Granted 312,081 26.61 268,738 25.19 Vested (325,561) 27.84 (30,616) 51.65 Non-vested at year end 495,686 $ 25.69 509,166 $ 26.50 On February 8, 2021, the Company granted 30,616 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. On January 3, 2023, the Company determined the TSR attainment was 100% of the targeted shares, resulting in 30,616 shares being awarded and 30,616 shares vesting to current employees of the Company based on our total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of 20 of our peers. The market-based restricted stock awards were to vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 68%, 0% dividend yield, and a risk-free interest rate of 0.1%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate was based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $1.3 million was expensed on a straight-line basis over the grant date to the vesting date of December 31, 2022. On February 24, 2022, the Company granted 240,428 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. On March 8, 2024, the Company’s Compensation Committee determined the TSR attainment was 125% of the targeted shares and 300,529 shares were awarded to the executives of the Company based on our TSR during the period beginning on January 1, 2022 through December 31, 2023 as compared to the TSR of 20 of our peers. The market-based restricted stock awards were to vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 63%, 0% dividend yield, and a risk-free interest rate of 1.5%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate was based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.7 million was expensed on a straight-line basis over the grant date to the vesting date of December 31, 2023. On January 3, 2023, the Company granted 268,738 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 78%, 0% dividend yield, and a risk-free interest rate of 4.4%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate was based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024. On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2024 through December 31, 2025 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 80%, 0% dividend yield and a risk-free interest rate of 4.6%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.3 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2025. We recognized stock compensation expense of $4.5 million, $6.5 million, and $4.3 million related to market-based restricted stock awards for the years ended December 31, 2024, 2023, and 2022. As of December 31, 2024, there was $3.3 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. We expect to recognize those costs over 1 year. The aggregate fair value of the market-based awards granted during the years ended December 31, 2024, 2023, and 2022 was $6.3 million, $6.5 million, and $6.7 million, respectively. The aggregate fair value of the market-based awards that vested during the years ended December 31, 2024, 2023, and 2022 was $5.7 million, $0.7 million, and $5.0 million, respectively. Total stock compensation expense We recorded total stock compensation expense for the years ended December 31, 2024, 2023, and 2022, as follows: 2024 2023 2022 Research and development costs $ 2,273 $ 4,665 $ 2,423 Sales and marketing costs 1,765 3,615 2,456 General and administrative costs 10,864 13,447 11,524 Cost of revenue 1,612 1,522 1,323 Total $ 16,514 $ 23,249 $ 17,726

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income tax benefit from continuing operations consists of the following: Year Ended December 31, (In thousands) 2024 2023 2022 Current: State $ (26) $ (46) $ (11) Total current tax provision (26) (46) (11) Deferred: Federal 64 70 2,929 State — — 2,318 Total deferred tax provision 64 70 5,247 Income tax benefit $ 38 $ 24 $ 5,236 The Company's (loss) income from continuing operations before income tax benefit did not contain any foreign components as of December 31, 2024, 2023, and 2022. The tax benefit for the year ended December 31, 2024 contained excess tax benefits from stock-based compensation of $0.3 million. The tax benefit for the years ended December 31, 2023, and 2022 did not contain excess tax benefits from stock-based compensation. A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows: Year Ended December 31, 2024 2023 2022 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 6 % 4 % 11 % Stock compensation 4 % (5 %) — % Sec. 162(m) limitation on executive compensation (4 %) (6 %) (30 %) Fair value change in contingent consideration — % 2 % 21 % Tax credits 4 % 4 % 17 % Change in valuation allowance (27 %) (24 %) 74 % Gain on escrow settlement — % 5 % — % Other (4 %) (1 %) (6 %) Total — % — % 108 % The principal components of the Company’s net deferred tax liabilities are as follows as of December 31, 2024 and 2023: (In thousands) 2024 2023 Deferred tax assets related to: Net operating loss carryforwards $ 39,079 $ 35,505 Capital loss carryforward 7,011 — Tax credit carryforward 2,695 2,226 Stock-based compensation 2,141 3,008 Accruals and reserves 1,883 3,590 Inventory 1,410 1,408 Fixed assets 568 585 Lease liabilities 3,540 3,950 Capitalized research and development 3,222 4,818 Fair value change in investments 556 — Other 1,084 875 Total deferred tax assets 63,189 55,965 Deferred tax liabilities related to: Intangibles (2,326) (3,696) Right-of-use assets (2,654) (2,500) Fair value change in investments — (440) Total deferred tax liabilities (4,980) (6,636) Net deferred tax assets before valuation allowance 58,209 49,329 Less: valuation allowance 58,333 49,517 Net deferred tax liabilities (124) (188) Less: deferred tax liability, discontinued operations — (74) Net deferred tax liabilities, continuing operations $ (124) $ (114) Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. The assessment regarding whether a valuation allowance is required on deferred tax assets considers the evaluation of both positive and negative evidence when concluding whether it is more likely than not that deferred tax assets are realizable. The valuation allowance recorded as of December 31, 2024 and 2023 primarily relates to deferred tax assets for net operating loss carryforwards. The changes in the valuation allowance for deferred tax assets were as follows: (In thousands) 2024 2023 2022 Balance at beginning of period $ 49,517 $ 33,402 $ 2,993 Net deferred tax assets divested (7,173) — — Charged to income tax expense 15,989 16,115 30,409 Balance at end of period $ 58,333 $ 49,517 $ 33,402 As of December 31, 2024, the Company had U.S. federal net operating loss (“NOL”) carryforwards of approximately $165.2 million. Approximately $38.7 million of NOL will expire from 2025 through 2037, and approximately $126.5 million of NOL will be carried forward indefinitely. The NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest. This limited the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership changes may further affect the limitation in future years. The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. A reconciliation of the beginning and ending balances of uncertain tax positions in the years ended December 31, 2024 and 2023 is as follows: (In thousands) 2024 2023 Balance at beginning of period $ 954 $ 610 Increase related to prior year tax positions — 20 Increase related to current year tax positions 201 324 Balance at end of period $ 1,155 $ 954 The Company is generally subject to examination by U.S. federal and local income tax authorities for all tax years in which loss carryforward is available, which includes 2005 through 2024.

Segment, customer, and geograph

Segment, customer, and geographic information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment, customer, and geographic information	Segment, customer, and geographic information The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, Mr. Roderick de Greef, who is the CODM, reviews the Company’s operations on a consolidated basis for purposes of allocating resources and evaluating financial performance. As a single reportable segment entity, the Company’s segment performance measure is consolidated net (loss) income from continuing operations. Significant segment expenses are presented in the Company’s Consolidated Statements of Operations. Additional significant segment expenses that are not separately presented in the Company’s Consolidated Statements of Operations include Shared-based compensation and Depreciation expense. These are presented in the Consolidated Statement of Cash Flows, and Note 14: Stock-based compensation , Note 8: Assets held for rent , and Note 9: Property and equipment. Other expense items not individually significant in net (loss) income from continuing operations are changes in inventory values due to changes in its carrying basis, costs associated with the Company’s acquisitions and or divestitures in the period these take place, and gain or loss on disposal of fixed assets. The information provided to the Company’s CODM for purposes of making decisions and assessing segment performance excludes asset information. Concentrations of risk Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue December 31, Years Ended December 31, 2024 2023 2024 2023 2022 Customer A 18 % * 15 % 14 % 18 % Customer B 21 % 13 % 13 % 11 % 14 % *less than 10% The following is a summary of revenue by major product family representing over 10% of the Company's total revenue: Years Ended December 31, Revenue by major product 2024 2023 2022 CryoStor 73 % 73 % 77 % The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Years Ended December 31, Revenue by customers’ geographic locations (1) 2024 2023 2022 United States 75 % 82 % 82 % Europe, Middle East, Africa (EMEA) 19 % 12 % 12 % Other 6 % 6 % 6 % Total revenue 100 % 100 % 100 % (1) During the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented. All of the Company's long-lived assets, totaling $22.9 million , are located within the United States. In the year ended December 31, 2024, no suppliers accounted for more than 10% of purchases. In the years ended December 31, 2023, and 2022, one supplier accounted for 20% and 16% of purchases, respectively. As of December 31, 2024, no suppliers accounted for more than 10% of accounts payable. As of December 31, 2023, one supplier accounted for 17% of accounts payable. No other suppliers accounted for more than 10% of our accounts payable.

Employee benefit plan

Employee benefit plan	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Employee benefit plan	Employee benefit plan The Company sponsors 401(k) defined contribution plans for its employees. These plans provide for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to these plans, as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made contributions of $0.6 million, $0.5 million, and $0.4 million to the plans for the years ended December 31, 2024, 2023, and 2022.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent events	Subsequent events The Company has evaluated events subsequent to December 31, 2024 through the date of this filing to assess the need for potential recognition or disclosure. Based upon this evaluation, it was determined that no subsequent events occurred that require recognition or disclosure in the Consolidated Financial Statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (20,184)	$ (68,002)	$ (139,805)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		The following table identifies and provides the material terms of the Rule 10b5-1 trading arrangements (as such term is defined in Item 408 of Regulation S-K) adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended December 31, 2024. Name and Position Plan Adoption / Termination Plan Adoption / Termination Date Expiration Date Number of Shares Purchased (Sold) / Terminated under Plan Sarah Aebersold, Chief Human Resources Officer Adoption December 11, 2024 December 17, 2025 (7,324) Amy DuRoss, Lead Director Adoption December 13, 2024 September 12, 2025 (5,632) Joydeep Goswami, Director Adoption December 13, 2024 December 13, 2025 (9,000)
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Sarah Aebersold [Member]
Trading Arrangements, by Individual
Name	Sarah Aebersold
Title	Chief Human Resources Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 11, 2024
Expiration Date	December 17, 2025
Arrangement Duration	371 days
Aggregate Available	7,324	7,324
Amy DuRoss [Member]
Trading Arrangements, by Individual
Name	Amy DuRoss
Title	Lead Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 13, 2024
Expiration Date	September 12, 2025
Arrangement Duration	273 days
Aggregate Available	5,632	5,632
Joydeep Goswami [Member]
Trading Arrangements, by Individual
Name	Joydeep Goswami
Title	Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 13, 2024
Expiration Date	December 13, 2025
Arrangement Duration	365 days
Aggregate Available	9,000	9,000

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	We have a thorough process for identifying, assessing, and managing cybersecurity risks within our broader risk management framework. We gather insights from external experts and internal threat intelligence teams for our cybersecurity risk management program. A dedicated team oversees cybersecurity risk management, led by professionals with deep expertise, including our Vice President, Cybersecurity and Information Security Officer. Our executive leadership, supported by our cybersecurity team, oversees our enterprise risk management and regularly considers cybersecurity and other material risks. Within our cybersecurity risk management system, our incident management team tracks and logs privacy and security incidents across the Company and third-party service providers. Significant incidents undergo review by a cross-functional group, with immediate escalation for potentially material incidents. We consult with outside counsel as needed, with final decisions made by senior management.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have a thorough process for identifying, assessing, and managing cybersecurity risks within our broader risk management framework.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Audit Committee oversees cybersecurity risks and incidents, ensuring compliance with disclosure requirements and cooperation with law enforcement. Senior management regularly updates the committee on cyber risks and any material incidents.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee oversees cybersecurity risks and incidents, ensuring compliance with disclosure requirements and cooperation with law enforcement. Senior management regularly updates the committee on cyber risks and any material incidents.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Senior management regularly updates the committee on cyber risks and any material incidents.
Cybersecurity Risk Role of Management [Text Block]	We have a thorough process for identifying, assessing, and managing cybersecurity risks within our broader risk management framework. We gather insights from external experts and internal threat intelligence teams for our cybersecurity risk management program. A dedicated team oversees cybersecurity risk management, led by professionals with deep expertise, including our Vice President, Cybersecurity and Information Security Officer. Our executive leadership, supported by our cybersecurity team, oversees our enterprise risk management and regularly considers cybersecurity and other material risks. Within our cybersecurity risk management system, our incident management team tracks and logs privacy and security incidents across the Company and third-party service providers. Significant incidents undergo review by a cross-functional group, with immediate escalation for potentially material incidents. We consult with outside counsel as needed, with final decisions made by senior management. The Audit Committee oversees cybersecurity risks and incidents, ensuring compliance with disclosure requirements and cooperation with law enforcement. Senior management regularly updates the committee on cyber risks and any material incidents.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	A dedicated team oversees cybersecurity risk management, led by professionals with deep expertise, including our Vice President, Cybersecurity and Information Security Officer. Our executive leadership, supported by our cybersecurity team, oversees our enterprise risk management and regularly considers cybersecurity and other material risks.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	A dedicated team oversees cybersecurity risk management, led by professionals with deep expertise, including our Vice President, Cybersecurity and Information Security Officer
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Audit Committee oversees cybersecurity risks and incidents, ensuring compliance with disclosure requirements and cooperation with law enforcement. Senior management regularly updates the committee on cyber risks and any material incidents.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Organization and significant _2

Organization and significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions by management affect the Company’s allowance for credit losses, the net realizable value of inventory, sales tax liabilities, valuation of market based stock awards, valuations related to investments and transaction activities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, certain accrued expenses, share-based compensation, and the provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation and consolidation	Basis of presentation and consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Operations. The Consolidated Statements Of Comprehensive Loss, Consolidated Statements of Shareholders' Equity, and Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 3: Discontinued operations for additional details about the divestitures. All long-lived assets are maintained in the United States of America.
Segment reporting	Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Revenue recognition	Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers , we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the observable and estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. During the year ended December 31, 2024, the Company recognized approximately $39 thousand of revenue that was included in the deferred revenue balance at the beginning of the year. The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, hPL media, evo ModPaks, and ThawSTAR products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statements of Operations. Service revenues are generated from various customer service agreements to provide warranty and other engineering services. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the year ended December 31, 2024. The Company generates revenue from the leasing of our evo cold chain systems to customers pursuant to rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases . All customers leasing shippers currently do so under rental arrangements for durations of one year or less, with each unit having the option to continue its rental arrangement on a month-to-month basis until returned to the Company beyond the initial rental period. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term. Total bioproduction products and services revenue for the years ended December 31, 2024, 2023, and 2022 were comprised of the following: Years Ended December 31, (In thousands, except percentages) 2024 2023 2022 Product revenue Cell processing $ 73,446 $ 65,772 $ 68,509 Evo and thaw 2,582 3,196 3,434 Service revenue Evo and thaw 160 349 73 Rental revenue Evo and thaw 6,066 6,538 4,223 Total revenue $ 82,254 $ 75,855 $ 76,239 There was no estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods as of December 31, 2024. The Company elected not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers . For additional information on the Company's revenues by geographic region, product line, and other customer concentration information, see Note 16: Segment, customer, and geographic information .
Risk and uncertainties	Risks and uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.
(Loss) earnings per share from continuing operations	(Loss) earnings per share from continuing operations Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.
Cash and cash equivalents	Cash and cash equivalents Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three months or less to be cash equivalents. We maintain cash balances that may exceed federally insured limits. We do not believe that this results in any significant credit risk.
Available-for-sale securities	Available-for-sale securities Available-for-sale securities consist of U.S. government securities, corporate debt securities, and other debt securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale securities are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive (loss) income, net of any related tax effect. Realized gains and losses and other-than-temporary impairments on investments are included in other income.
Inventories	Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. The Company values thaw inventory at cost or, if lower, net realizable value, using the average costing method. All other inventory is valued at cost or, if lower, net realizable value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected revenue volume to cost of product revenue. The Company bases its estimates on expected product revenue volume, production capacity and expiration dates of raw materials, work in process, and finished products. A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During the year ended December 31, 2023, we assessed write-downs of approximately $3.4 million and recorded within the line item Inventories in the Company's Consolidated Balance Sheet. For additional information, see Note 6: Inventories . Work-in-process and finished products inventories consist of material, labor, outside testing costs and manufacturing overhead.
Accounts receivable	Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 to 90 days) and are stated at the amount we expect to collect. We establish an allowance for credit losses based on our assessment of the collectability of specific customer accounts. Accounts considered uncollectible are charged against the established allowance. Accounts receivable are stated at principal amount, do not bear interest, and are generally unsecured. Accounts considered uncollectible are charged against the established allowance.
Equity investments	Equity investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2024 and December 31, 2023, our investment in Series E Preferred Stock in PanTHERA CryoSolutions, Inc. (“PanTHERA”) was valued at $1.0 million. In November of 2020, the Company invested $1.0 million in Class E Preferred Shares in PanTHERA CryoSolutions, Inc. In conjunction with this investment, the Company executed a development and license agreement with PanTHERA under which the Company will make milestone development payments up to $2.0 million in the event that certain milestones are met in exchange for exclusive, perpetual, worldwide marketing and distribution rights to the technology for use in cell and gene therapy applications. As of December 31, 2024, the Company has paid $1.9 million in milestone development payments, with $0.9 million paid during the current year in accordance with the agreement. The Preferred Stock investments in PanTHERA are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar investments of the same issuer. As of December 31, 2024, management believes there are no indications of impairment or changes in fair value for the investment in PanTHERA.
Property and equipment and Long-Lived Assets	Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three Long-Lived Assets The Company reviews long-lived assets, including property and equipment, leased assets, and definite life intangible assets for impairment whenever events and changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest level for which identifiable independent cash flows are available ("asset group"). An impairment loss is recognized when the sum of the projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach or cost approach.
Assets held for rent	Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of evo shippers and related components in production, shippers complete, ready to be deployed, and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Shippers are depreciated over a useful life of three years when in use by customers. Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. Carrying values are reviewed for recoverability at the asset grouping level to determine if the facts and circumstances suggest that a potential impairment may have occurred. If the sum of the expected future cash flows (undiscounted and before interest) from the use of the assets is less than the net book value of the asset, an impairment could exist and the amount of the impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. There were no impairment losses recognized during the years ended December 31, 2024, 2023, and 2022.
Lease accounting	Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a financing lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than twelve months. Over the lease term we use the effective interest rate method to account for the lease liability as lease payments are made and the ROU asset is amortized in a manner that results in straight-line expense recognition. The Company has elected the practical expedient and does not separate lease components from non-lease components for its leases. We elected to apply the practical expedient for short-term leases and accordingly do not apply lease recognition requirements for short-term leases with a duration less than twelve months. Instead, we recognize payments related to these arrangements in the Consolidated Statement of Operations as lease costs on a straight-line basis over the lease term.
Warranty	Warranty Our standard warranty terms typically cover one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period.
Income taxes	Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not that the asset will not be realized. Our policy for interest and penalties is to recognize interest and penalties as a component of the provision for income taxes in the Consolidated Statement of Operations. We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2024, the Company has an unrecognized tax benefit of $1.2 million related to tax attributes being carried forward. The Company is generally subject to examination by U.S. federal and local income tax authorities for all tax years in which loss carryforward is available.
Sales Taxes Payable	Sales Taxes Payable The Company records sales tax collected from customers on a net basis, and therefore excludes it from total product, service and rental revenue as defined in ASC 606. Cash collected from customers is recorded in accrued expenses on the Company's Consolidated Balance Sheet and then remitted to the proper taxing authority. In addition, refer to Note 12: Commitments and contingencies
Advertising	Advertising Advertising costs are expensed as incurred and totaled $0.9 million, $0.8 million, and $0.4 million for the years ended December 31, 2024, 2023, and 2022, respectively.
Research and development	Research and development Research and development costs are expensed as incurred.
Stock-based compensation	Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards, and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not amortized but is tested for impairment at least annually. The Company reviews goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate that the fair value of a reporting unit may be less than its carrying amount (a triggering event). The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test described in FASB ASC Topic 350, Intangibles – Goodwill and Other . The more likely than not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the quantitative goodwill impairment test is unnecessary and goodwill is considered to be unimpaired. However, if based on the qualitative assessment the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company will proceed with performing the quantitative goodwill impairment test. In performing the quantitative goodwill impairment test, the Company determines the fair value of its reporting unit and compares it to its carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company records an impairment loss equal to the difference. The Company operates as one reporting unit as of the goodwill impairment measurement date in the fourth quarter of 2024. As of the testing date and the period after that date through the issuance date of our financial statements, the Company has observed no indicators of potential goodwill impairment at any point during the period based on its required assessment.
Intangible assets	Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable.
Recent accounting pronouncements	Recent accounting pronouncements Recently adopted accounting pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. We adopted this standard effective January 1, 2024 using a retrospective method. For additional information, refer to Note 16: Segment, customer, and geographic information . Recently issued accounting pronouncements not yet adopted In November 2024, FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses , which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements. In March 2024, the FASB issued ASU 2024-02, Codification Improvements to amend a variety of topics in the accounting codification by removing references to various FASB concepts statements. This accounting standard is effective for fiscal years beginning after December 15, 2024, and early adoption is permitted. ASU 2024-02 can be applied retrospectively to the beginning of the earliest comparative period presented in which the amendments were first applied or prospectively to all new transactions recognized on or after the date that the entity first applies the amendments. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires additional disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information increasing transparency of income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements. In October 2023 , the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in ASU 2023-06 update requirements in various disclosure areas, including the statement of cash flows, earnings per share, debt, and equity. The amendments in ASU 2023-06 will be effective on the date the related disclosures are removed from Regulation S-X or Regulation S-K by the SEC and will no longer be effective if the SEC has not removed the applicable disclosure requirement by June 30, 2027. Early adoption is prohibited. The Company has evaluated the impact of the adoption of ASU 2023-06 on its consolidated financial statements and disclosures, and has determined that the adoption of this guidance will not materially impact the Company’s current disclosures. In addition, the Company believes the adoption of ASU 2023-06 will not have a material impact on results of operations, cash flows, or financial condition.

Organization and significant _3

Organization and significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenues by Product Line	Total bioproduction products and services revenue for the years ended December 31, 2024, 2023, and 2022 were comprised of the following: Years Ended December 31, (In thousands, except percentages) 2024 2023 2022 Product revenue Cell processing $ 73,446 $ 65,772 $ 68,509 Evo and thaw 2,582 3,196 3,434 Service revenue Evo and thaw 160 349 73 Rental revenue Evo and thaw 6,066 6,538 4,223 Total revenue $ 82,254 $ 75,855 $ 76,239
Schedule of Earnings Per Share, Basic and Diluted	The following table presents computations of basic and diluted earnings per share: Year Ended December 31, (In thousands, except share and earnings per share data) 2024 2023 2022 Basic and diluted (loss) income from continuing operations per common share Numerator: (Loss) income from continuing operations $ (11,387) $ (18,447) $ 388 Denominator: Weighted-average common shares issued and outstanding - Basic 46,067,073 43,719,185 42,481,027 Effect of dilutive securities — — 592,446 Weighted-average common shares issued and outstanding - Diluted 46,067,073 43,719,185 43,073,473 Net (loss) income per share from continuing operations attributable to common shareholders Basic $ (0.25) $ (0.42) $ 0.01 Diluted $ (0.25) $ (0.42) $ 0.01 Anti-dilutive shares 1,283,885 647,348 —
Schedule of Product Revenue Concentration	The following is a summary of revenue by major product family representing over 10% of the Company's total revenue: Years Ended December 31, Revenue by major product 2024 2023 2022 CryoStor 73 % 73 % 77 %
Schedule of Revenue by Geographic Areas	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Years Ended December 31, Revenue by customers’ geographic locations (1) 2024 2023 2022 United States 75 % 82 % 82 % Europe, Middle East, Africa (EMEA) 19 % 12 % 12 % Other 6 % 6 % 6 % Total revenue 100 % 100 % 100 % (1) During the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.

Correction of immaterial erro_2

Correction of immaterial errors (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2023 was as follows: December 31, 2023 (In thousands) As reported Adjustment As corrected Additional paid-in-capital 651,305 1,575 652,880 Accumulated deficit (313,342) (1,575) (314,917) The effect of the adjustments to our Consolidated Statement of Operations for the year ended December 31, 2023 was as follows: December 31, 2023 (In thousands, except share and earnings per share data) As reported Adjustment As corrected General and administrative 55,725 1,414 57,139 Research and development 24,583 161 24,744 Total operating expenses 214,096 1,575 215,671 Operating loss (70,825) (1,575) (72,400) Loss from continuing operations before income tax benefit (66,258) (1,575) (67,833) Loss from continuing operations (66,427) (1,575) (68,002) Net loss per basic and diluted share from continuing operations (1.52) (0.04) (1.56) The effect of the adjustments to our Consolidated Statement of Cash Flows for the year ended December 31, 2023 was as follows: December 31, 2023 (In thousands, except share and earnings per share data) As reported Adjustment As corrected Net loss (66,427) (1,575) (68,002) Stock-based compensation 31,670 1,575 33,245

Discontinued operations (Tables

Discontinued operations (Tables)	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations	The Company recognized a loss on disposal of Global Cooling, calculated as follows: (In thousands) Selling price: $1 $ — Cash to Global Cooling funded by Company (6,652) Costs to sell Global Cooling (1) (582) Negative selling price (7,234) Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities (3,589) Assumed liabilities: Accounts payable (2) 2,643 Assumed liabilities: Debt (3) 2,596 Less: Global Cooling carrying basis as of April 17, 2024 1,650 Less: Release of Global Cooling currency translation adjustment (13) Net loss on disposal $ (8,897) (1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties. (2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively. (3) As a closing condition, the Company repaid the balance of all obligations of Global Cooling under that certain promissory note payable by Global Cooling to a lender (the "Global Cooling Term Notes"). (In thousands) Severance Stock Compensation Total RIF employee costs $ 291 $ 1,255 $ 1,546 Former Global Cooling employees — 1,925 1,925 Total employment related divestiture expenditures $ 291 $ 3,180 $ 3,471 The Company recognized a gain on disposal of SciSafe, calculated as follows: (In thousands) Cash proceeds received from Buyer $ 71,291 Cash proceeds from escrow 483 Costs to sell (1) (506) Total proceeds 71,268 Less: SciSafe carrying basis as of November 12, 2024 42,507 Less: Release of SciSafe currency translation adjustment 622 Net gain on disposal $ 28,139 The Company recognized a loss on disposal of CBS, calculated as follows: (In thousands) Cash proceeds received from Buyer $ 2,785 Cash proceeds from escrow 615 Net price adjustment (1) 179 Costs to sell (2) (148) Total proceeds 3,431 Less: CBS carrying basis as of November 14, 2024 6,796 Net loss on disposal $ (3,365) (1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the disposal. (2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million. The table below summarizes the major classes of assets and liabilities of discontinued operations, which are summarized separately in the Consolidated Balance Sheets: December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Cash and cash equivalents $ 2,090 $ 5,102 $ 340 $ 7,532 Restricted cash — — 10 10 Accounts receivable, net 1,728 6,353 2,677 10,758 Inventories 11,248 — 5,044 16,292 Prepaid expenses and other current assets 303 895 901 2,099 Total current assets, discontinued operations 15,369 12,350 8,972 36,691 Assets held for rent, net — 796 — 796 Property and equipment, net 146 15,241 — 15,387 Operating lease right-of-use assets, net — 4,568 — 4,568 Financing lease right-of-use assets, net — 94 — 94 Long-term deposits and other assets 4 199 — 203 Intangible assets, net — 9,153 — 9,153 Goodwill — 11,333 1,104 12,437 Total assets, discontinued operations 15,519 53,734 10,076 79,329 Accounts payable 3,367 578 726 4,671 Accrued expenses and other current liabilities 1,156 1,300 573 3,029 Sales taxes payable 481 44 518 1,043 Warranty liability 7,507 — 131 7,638 Lease liabilities, operating, current portion 263 1,249 — 1,512 Lease liabilities, financing, current portion 22 74 280 376 Debt, current portion — 447 100 547 Total current liabilities, discontinued operations 12,796 3,692 2,328 18,816 Lease liabilities, operating, long-term 1,016 3,494 — 4,510 Lease liabilities, financing, long-term 11 27 1,130 1,168 Debt, long-term — 679 72 751 Deferred tax liabilities — — 74 74 Total liabilities, discontinued operations $ 13,823 $ 7,892 $ 3,604 $ 25,319 The key components of loss from discontinued operations were as follows: December 31, 2024 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 7,157 $ 18,440 $ 12,141 $ 37,738 Cost of revenue (8,389) (16,357) (10,600) (35,346) Operating expenses (9,418) (11,467) (4,967) (25,852) Intangible asset amortization — (764) — (764) Other expense, net (25) (183) (110) (318) (Loss) gain on disposal (8,897) 28,139 (3,365) 15,877 (Loss) income before income taxes (19,572) 17,808 (6,901) (8,665) Income tax expense (10) (122) — (132) (Loss) income from discontinued operations, net of income taxes $ (19,582) $ 17,686 $ (6,901) $ (8,797) December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 35,826 $ 18,014 $ 13,576 $ 67,416 Cost of revenue (36,682) (17,283) (12,632) (66,597) Operating expenses (20,162) (5,316) (7,153) (32,631) Intangible asset impairment charges (7,175) — (8,310) (15,485) Intangible asset amortization (131) (907) (623) (1,661) Other expense, net (90) (100) (214) (404) Loss before income taxes (28,414) (5,592) (15,356) (49,362) Income tax expense (4) (180) (9) (193) Loss from discontinued operations, net of income taxes $ (28,418) $ (5,772) $ (15,365) $ (49,555) December 31, 2022 (In thousands) Global Cooling SciSafe CBS Total Revenue $ 47,915 $ 21,462 $ 16,142 $ 85,519 Cost of revenue (51,621) (15,060) (11,928) (78,609) Operating expenses (19,211) (5,697) (5,548) (30,456) Intangible asset impairment charges (110,364) — — (110,364) Intangible asset amortization (3,969) (907) (830) (5,706) Other expense, net (255) (84) (24) (363) Loss before income taxes (137,505) (286) (2,188) (139,979) Income tax expense (14) (191) (9) (214) Loss from discontinued operations, net of income taxes $ (137,519) $ (477) $ (2,197) $ (140,193) Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations: December 31, 2024 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ — $ 2,402 $ 4 $ 2,406 Amortization — 764 — 764 Stock-based compensation 4,191 6,410 3,790 14,391 Interest expense, net 42 50 114 206 Capital expenditures — 2,200 720 2,920 December 31, 2023 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ 397 $ 2,636 $ 471 $ 3,504 Amortization 131 907 623 1,661 Stock-based compensation 4,734 2,759 2,503 9,996 Interest expense, net 131 13 219 363 Capital expenditures — 4,659 750 5,409 December 31, 2022 (In thousands) Global Cooling SciSafe CBS Total Depreciation $ 616 $ 2,081 $ 488 $ 3,185 Amortization 3,969 907 830 5,706 Stock-based compensation 3,304 2,465 1,839 7,608 Interest expense, net 257 118 28 403 Capital expenditures — 6,790 812 7,602

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023, based on the three-tier fair value hierarchy: (In thousands) As of December 31, 2024 Level 1 Level 2 Total Assets: Cash equivalents: Money market accounts $ 89,119 — $ 89,119 Available-for-sale securities: U.S. government securities 1,494 — 1,494 Corporate debt securities 398 8,602 9,000 Other debt securities — 3,332 3,332 Total 91,011 11,934 102,945 As of December 31, 2023 Level 1 Level 2 Total Assets: Cash equivalents: Money market accounts $ 25,034 — $ 25,034 Available-for-sale securities: U.S. government securities 5,170 — 5,170 Corporate debt securities — 9,674 9,674 Other debt securities — 1,992 1,992 Total 30,204 11,666 41,870
Schedule of the Changes in Fair Value of Contingent Consideration Liabilities	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs for the year ended December 31, 2023: Year Ended December 31, (In thousands) 2023 Balance at beginning of period $ 4,456 Change in fair value recognized in net loss from continuing operations (2,193) Payment of contingent consideration earned (2,263) Balance at end of period $ —

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Marketable Securities	The Company’s portfolio of available-for-sale marketable securities consists of the following: December 31, 2024 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 1,493 $ 1 $ — $ 1,494 Corporate debt securities 5,775 14 (1) 5,788 Other debt securities 1,912 4 — 1,916 Total short-term 9,180 19 (1) 9,198 Available-for-sale securities, long-term Corporate debt securities 3,210 4 (2) 3,212 Other debt securities 1,412 5 (1) 1,416 Total available-for-sale securities $ 13,802 $ 28 $ (4) $ 13,826 December 31, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,169 $ 1 $ — $ 5,170 Corporate debt securities 9,673 5 (4) 9,674 Other debt securities 1,443 1 — 1,444 Total short-term 16,285 7 (4) 16,288 Available-for-sale securities, long-term Other debt securities 545 3 — 548 Total available-for-sale securities $ 16,830 $ 10 $ (4) $ 16,836 The following table summarizes the contractual maturities of the short-term and long-term available-for-sale investments as of December 31, 2024: (In thousands) Amortized Estimated Due in one year or less $ 9,180 $ 9,198 Due after one year through five years 4,622 4,628 Total $ 13,802 $ 13,826
Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value	The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months: December 31, 2024 Less than 12 months Total (In thousands) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,091 $ (3) $ 2,091 $ (3) Other debt securities 1,030 (1) 1,030 (1) Total $ 3,121 $ (4) $ 3,121 $ (4) December 31, 2023 Less than 12 months Total (In thousands) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 5,871 $ (4) $ 5,871 $ (4) Other debt securities 906 (1) 906 (1) Total $ 6,777 $ (5) $ 6,777 $ (5)

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Raw materials $ 11,768 $ 14,668 Work in progress 4,082 3,475 Finished goods 13,163 9,021 Total $ 29,013 $ 27,164

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Operating and Finance Lease Terms and Discount Rates	The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2024 and 2023: 2024 2023 Weighted average discount rate - operating leases 6.4 % 4.5 % Weighted average remaining lease term in years - operating leases 6.1 7.1
Schedule of Lease Expense	The components of lease expense for the years ended December 31, 2024, 2023, and 2022 were as follows: Year Ended December 31, (In thousands) 2024 2023 2022 Operating lease costs $ 1,997 $ 1,630 $ 1,560 Short-term lease costs 59 260 280 Total operating lease costs 2,056 1,890 1,840 Variable lease costs 1,103 797 677 Total lease expense $ 3,159 $ 2,687 $ 2,517
Schedule of Maturities of Operating Lease Liabilities	Maturities of our lease liabilities as of December 31, 2024 are as follows: (In thousands) Operating Leases 2025 $ 2,351 2026 3,029 2027 2,583 2028 2,642 2029 2,724 Thereafter 3,946 Total lease payments 17,275 Less: interest (3,041) Total present value of lease liabilities $ 14,234
Schedule of Maturities of Finance Lease Liabilities	Maturities of our lease liabilities as of December 31, 2024 are as follows: (In thousands) Operating Leases 2025 $ 2,351 2026 3,029 2027 2,583 2028 2,642 2029 2,724 Thereafter 3,946 Total lease payments 17,275 Less: interest (3,041) Total present value of lease liabilities $ 14,234

Assets held for rent (Tables)

Assets held for rent (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Assets Held for Rent	Assets held for rent consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Shippers placed in service $ 9,505 $ 9,866 Accumulated depreciation (6,499) (5,600) Net 3,006 4,266 Shippers and related components in production 3,097 2,651 Total $ 6,103 $ 6,917

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Property and equipment Leasehold improvements $ 3,527 $ 3,503 Furniture and computer equipment 306 596 Manufacturing and other equipment 4,073 3,340 Construction in-progress 2,478 2,513 Subtotal 10,384 9,952 Less: Accumulated depreciation (4,300) (4,263) Property and equipment, net $ 6,084 $ 5,689

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following as of December 31, 2024 and 2023: (In thousands) 2024 2023 Accrued expenses $ 7,116 $ 6,620 Accrued taxes — 264 Accrued compensation 5,232 2,196 Deferred revenue, current 103 41 Total accrued expenses and other current liabilities $ 12,451 $ 9,121

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	(In thousands) Goodwill Original acquired goodwill as of December 31, 2023 (1) $ 224,741 Less: Goodwill allocated to SciSafe in divestiture (11,333) Less: Goodwill allocated to CBS in divestiture (1,104) Balance as of December 31, 2024 $ 212,304 (1) As discussed in Note 3: Discontinued operations, the Company allocated a portion of its goodwill to each disposed entity in accordance with ASC 350. The goodwill balance presented above as of December 31, 2023 represents the balance of the reporting unit before the effect of the divestitures. The goodwill presented in the Consolidated Balance Sheets as of December 31, 2024 and 2023 is on a continuing operations basis giving effect to the divestitures.
Schedule of Finite-Lived Intangible Assets	Intangible assets, net consisted of the following as of December 31, 2024 and 2023: (In thousands, except weighted average useful life) December 31, 2024 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life Customer relationships $ 2,516 $ (2,508) $ 8 0.6 Tradenames 4,114 (1,799) 2,315 5.9 Technology - acquired 18,672 (11,436) 7,236 3.1 Non-compete agreements 90 (90) — 0.0 Total intangible assets $ 25,392 $ (15,833) $ 9,559 3.3 December 31, 2023 Intangible assets: Gross Carrying Value Accumulated Amortization (1) Net Carrying Value Weighted Average Useful Life Customer relationships $ 2,516 $ (2,495) $ 21 1.6 Tradenames 4,114 (1,389) 2,725 6.9 Technology - acquired 18,372 (9,122) 9,250 4.1 Non-compete agreements 90 (90) — 0.0 Total intangible assets $ 25,092 $ (13,096) $ 11,996 4.3
Schedule of Amortization Expense for Finite-Lived Intangible Assets	As of December 31, 2024, the Company expects to record the following amortization expense: (In thousands) For the Years Ending December 31, Estimated 2025 $ 2,807 2026 2,692 2027 1,938 2028 828 2029 530 Thereafter 764 Total $ 9,559

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt consisted of the following as of December 31, 2024 and 2023: December 31, (In thousands) Maturity Date Interest Rate 2024 2023 Global Cooling Term Notes (1) Various 4.0 % $ — $ 2,596 Term Loan (2) Jun-26 7.0 % 15,000 20,000 Insurance premium financing Various 8.3 % 975 1,348 Total debt, excluding unamortized debt issuance costs 15,975 23,944 Less: unamortized debt issuance costs (35) (98) Total debt 15,940 23,846 Less: current portion of debt (10,943) (6,285) Total long-term debt $ 4,997 $ 17,561 (1) The Company repaid the balance of all obligations of the Global Cooling Term Notes pursuant to the Global Cooling Purchase Agreement. (2) As of December 31, 2024, the Term Loan was secured by substantially all assets of BioLife, SAVSU, and Sexton, other than intellectual property.
Schedule of Maturities of Long-Term Debt	As of December 31, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2025 $ 10,943 2026 4,997 2027 — 2028 — 2029 — Thereafter — Total $ 15,940

Stock-based compensation (Table

Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Service Vesting-Based Stock Option Activity	The following is a summary of service vesting-based stock option activity for the year ended December 31, 2024 and 2023, and the status of service vesting-based stock options outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Shares Wtd. Avg. Outstanding as of beginning of year 217,250 $ 2.21 456,293 $ 2.17 Exercised (90,250) 2.23 (239,043) 2.12 Outstanding at end of year 127,000 $ 2.19 217,250 $ 2.21 Stock options exercisable at year end 127,000 $ 2.19 217,250 $ 2.21
Schedule of Share-Based Payment Arrangement, Option, Exercise Price Range	The following table summarizes information about service vesting-based stock options outstanding as of December 31, 2024: Range of Exercise Prices Number Outstanding at Weighted Average Weighted Average Exercise $1.00 - 1.50 2,000 1.85 $ 1.49 $1.51 - 2.00 115,000 1.32 1.89 $2.51 - 8.60 10,000 2.92 5.69 127,000 1.45 $ 2.19
Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity	The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2024 and 2023, and the status of unvested service vesting-based restricted stock outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Grant Shares Wtd. Avg. Grant Outstanding as of beginning of year 2,312,898 $ 18.32 1,879,215 $ 28.94 Granted 484,886 20.65 1,907,101 13.12 Vested (1,323,729) 21.57 (1,237,221) 24.97 Forfeited (178,415) 17.09 (236,197) 25.88 Non-vested at year end 1,295,640 $ 16.00 2,312,898 $ 18.32 The following is a summary of market-based restricted stock activity under our stock option plan for the years ended December 31, 2024 and 2023 and the status of market-based restricted stock outstanding as of December 31, 2024 and 2023: 2024 2023 Shares Wtd. Avg. Grant Date Fair Shares Wtd. Avg. Grant Date Fair Outstanding as of beginning of year 509,166 $ 26.50 271,044 $ 30.64 Granted 312,081 26.61 268,738 25.19 Vested (325,561) 27.84 (30,616) 51.65 Non-vested at year end 495,686 $ 25.69 509,166 $ 26.50
Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount	We recorded total stock compensation expense for the years ended December 31, 2024, 2023, and 2022, as follows: 2024 2023 2022 Research and development costs $ 2,273 $ 4,665 $ 2,423 Sales and marketing costs 1,765 3,615 2,456 General and administrative costs 10,864 13,447 11,524 Cost of revenue 1,612 1,522 1,323 Total $ 16,514 $ 23,249 $ 17,726

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	Income tax benefit from continuing operations consists of the following: Year Ended December 31, (In thousands) 2024 2023 2022 Current: State $ (26) $ (46) $ (11) Total current tax provision (26) (46) (11) Deferred: Federal 64 70 2,929 State — — 2,318 Total deferred tax provision 64 70 5,247 Income tax benefit $ 38 $ 24 $ 5,236
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows: Year Ended December 31, 2024 2023 2022 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 6 % 4 % 11 % Stock compensation 4 % (5 %) — % Sec. 162(m) limitation on executive compensation (4 %) (6 %) (30 %) Fair value change in contingent consideration — % 2 % 21 % Tax credits 4 % 4 % 17 % Change in valuation allowance (27 %) (24 %) 74 % Gain on escrow settlement — % 5 % — % Other (4 %) (1 %) (6 %) Total — % — % 108 %
Schedule of Deferred Tax Assets and Liabilities	The principal components of the Company’s net deferred tax liabilities are as follows as of December 31, 2024 and 2023: (In thousands) 2024 2023 Deferred tax assets related to: Net operating loss carryforwards $ 39,079 $ 35,505 Capital loss carryforward 7,011 — Tax credit carryforward 2,695 2,226 Stock-based compensation 2,141 3,008 Accruals and reserves 1,883 3,590 Inventory 1,410 1,408 Fixed assets 568 585 Lease liabilities 3,540 3,950 Capitalized research and development 3,222 4,818 Fair value change in investments 556 — Other 1,084 875 Total deferred tax assets 63,189 55,965 Deferred tax liabilities related to: Intangibles (2,326) (3,696) Right-of-use assets (2,654) (2,500) Fair value change in investments — (440) Total deferred tax liabilities (4,980) (6,636) Net deferred tax assets before valuation allowance 58,209 49,329 Less: valuation allowance 58,333 49,517 Net deferred tax liabilities (124) (188) Less: deferred tax liability, discontinued operations — (74) Net deferred tax liabilities, continuing operations $ (124) $ (114)
Schedule of Valuation Allowance	The changes in the valuation allowance for deferred tax assets were as follows: (In thousands) 2024 2023 2022 Balance at beginning of period $ 49,517 $ 33,402 $ 2,993 Net deferred tax assets divested (7,173) — — Charged to income tax expense 15,989 16,115 30,409 Balance at end of period $ 58,333 $ 49,517 $ 33,402
Schedule of Unrecognized Tax Benefits Roll Forward	A reconciliation of the beginning and ending balances of uncertain tax positions in the years ended December 31, 2024 and 2023 is as follows: (In thousands) 2024 2023 Balance at beginning of period $ 954 $ 610 Increase related to prior year tax positions — 20 Increase related to current year tax positions 201 324 Balance at end of period $ 1,155 $ 954

Segment, customer, and geogra_2

Segment, customer, and geographic information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedules of Concentration of Risk, by Risk Factor	Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue December 31, Years Ended December 31, 2024 2023 2024 2023 2022 Customer A 18 % * 15 % 14 % 18 % Customer B 21 % 13 % 13 % 11 % 14 %
Schedule of Product Revenue Concentration	The following is a summary of revenue by major product family representing over 10% of the Company's total revenue: Years Ended December 31, Revenue by major product 2024 2023 2022 CryoStor 73 % 73 % 77 %
Schedule of Revenue by Geographic Areas	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Years Ended December 31, Revenue by customers’ geographic locations (1) 2024 2023 2022 United States 75 % 82 % 82 % Europe, Middle East, Africa (EMEA) 19 % 12 % 12 % Other 6 % 6 % 6 % Total revenue 100 % 100 % 100 % (1) During the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.

Organization and significant _4

Organization and significant accounting policies - Narrative (Details)	1 Months Ended	6 Months Ended	12 Months Ended
	Nov. 30, 2020 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) reportable_segment reporting_unit	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Short-Term Debt [Line Items]
Number of reportable segments | reportable_segment			1
Number of reportable units | reporting_unit			1
Contract with customer, liability, revenue recognized			$ 39,000
Inventory write-down				$ 3,400,000
Standard warranty, term			1 year
Unrecognized tax benefits			$ 1,155,000	954,000	$ 610,000
Sales and excise tax payable			4,300,000	4,400,000
Advertising expense			$ 900,000	$ 800,000	$ 400,000
Impairment intangible asset, statement of income or comprehensive income, extensible enumeration not disclosed, flag			false	false	false
Interest Expense
Short-Term Debt [Line Items]
Sales and excise tax payable			$ 400,000	$ 400,000	$ 0
Tax Attributes Carried Forward
Short-Term Debt [Line Items]
Unrecognized tax benefits			$ 1,200,000
Assets Held for Rent
Short-Term Debt [Line Items]
Property, plant and equipment, useful life			3 years
Impairment of intangible assets (excluding goodwill)			$ 0	0	0
Minimum
Short-Term Debt [Line Items]
Property, plant and equipment, useful life			3 years
Maximum
Short-Term Debt [Line Items]
Property, plant and equipment, useful life			10 years
iVexSol, Inc.
Short-Term Debt [Line Items]
Equity securities without readily determinable fair value, amount				4,100,000	$ 4,100,000
iVexSol, Inc. | Series A-1 and A-2, Preferred Stock
Short-Term Debt [Line Items]
Equity securities without readily determinable fair value, amount				4,100,000
Impairment charge		$ 4,100,000
iVexSol, Inc. | Series A-2 Preferred Stock
Short-Term Debt [Line Items]
Equity securities without readily determinable fair value, amount	$ 1,000,000
PanTHERA CryoSolutions, Inc. | Series E Preferred Stock
Short-Term Debt [Line Items]
Equity securities without readily determinable fair value, amount			$ 1,000,000	$ 1,000,000
PanTHERA CryoSolutions, Inc. | Preferred Stock, Class E
Short-Term Debt [Line Items]
Contingent milestone payment	2,000,000
Contingent milestone paid			1,900,000
Milestone payment, paid during the year			$ 900,000
PanTHERA CryoSolutions, Inc. | Preferred Stock, Class E | PanTHERA Cryosolutions Investment
Short-Term Debt [Line Items]
Equity securities without readily determinable fair value, amount	$ 1,000,000

Organization and significant _5

Organization and significant accounting policies - Schedule of Revenues by Product Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 82,254	$ 75,855	$ 76,239
Product, Cell Processing
Disaggregation of Revenue [Line Items]
Total revenue	73,446	65,772	68,509
Product, Evo and thaw
Disaggregation of Revenue [Line Items]
Total revenue	2,582	3,196	3,434
Service, Evo and thaw
Disaggregation of Revenue [Line Items]
Total revenue	160	349	73
Rental, Evo and thaw
Disaggregation of Revenue [Line Items]
Total revenue	$ 6,066	$ 6,538	$ 4,223

Organization and significant _6

Organization and significant accounting policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Numerator:
(Loss) income from continuing operations	$ (11,387)	$ (18,447)	$ 388
Denominator:
Weighted-average common shares issued, Basic (in shares)	46,067,073	43,719,185	42,481,027
Weighted-average common shares issued and outstanding (in shares)	46,067,073	43,719,185	42,481,027
Effect of dilutive securities (in shares)	0	0	592,446
Weighted-average common shares issued, Diluted (in shares)	46,067,073	43,719,185	43,073,473
Weighted-average common shares outstanding, Diluted (in shares)	46,067,073	43,719,185	43,073,473
Net (loss) income per share from continuing operations attributable to common shareholders
Basic (in dollars per share)	$ (0.25)	$ (0.42)	$ 0.01
Diluted (in dollars per share)	$ (0.25)	$ (0.42)	$ 0.01
Anti-dilutive shares (in shares)	1,283,885	647,348	0

Organization and significant _7

Organization and significant accounting policies - Schedule of Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01	Dec. 31, 2024
Rental revenue
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Service revenue
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Correction of immaterial erro_3

Correction of immaterial errors - Schedule of effect of the adjustments to Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit	$ (335,101)	$ (314,917)
Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in-capital		652,880
Accumulated deficit		(314,917)
As reported | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in-capital		651,305
Accumulated deficit		(313,342)
Adjustment | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in-capital		1,575
Accumulated deficit		$ (1,575)

Correction of immaterial erro_4

Correction of immaterial errors - Schedule of effect of the adjustments to Consolidated Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative	$ 40,541	$ 43,264	$ 33,255
Research and development	7,912	12,073	8,671
Total operating expenses	89,383	99,295	82,162
Operating loss	(7,129)	(23,440)	(5,923)
Loss from continuing operations before income tax benefit	(11,425)	(18,471)	(4,848)
(Loss) income from continuing operations	$ (11,387)	$ (18,447)	$ 388
Net loss per basic share from continuing operations (in dollars per share)	$ (0.25)	$ (0.42)	$ 0.01
Net loss per diluted share from continuing operations (in dollars per share)	$ (0.25)	$ (0.42)	$ 0.01
Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative		$ 57,139
Research and development		24,744
Total operating expenses		215,671
Operating loss		(72,400)
Loss from continuing operations before income tax benefit		(67,833)
(Loss) income from continuing operations		$ (68,002)
Net loss per basic share from continuing operations (in dollars per share)		$ (1.56)
Net loss per diluted share from continuing operations (in dollars per share)		$ (1.56)
As reported | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative		$ 55,725
Research and development		24,583
Total operating expenses		214,096
Operating loss		(70,825)
Loss from continuing operations before income tax benefit		(66,258)
(Loss) income from continuing operations		$ (66,427)
Net loss per basic share from continuing operations (in dollars per share)		$ (1.52)
Net loss per diluted share from continuing operations (in dollars per share)		$ (1.52)
Adjustment | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative		$ 1,414
Research and development		161
Total operating expenses		1,575
Operating loss		(1,575)
Loss from continuing operations before income tax benefit		(1,575)
(Loss) income from continuing operations		$ (1,575)
Net loss per basic share from continuing operations (in dollars per share)		$ (0.04)
Net loss per diluted share from continuing operations (in dollars per share)		$ (0.04)

Correction of immaterial erro_5

Correction of immaterial errors - Schedule of effect of the adjustments to our Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss	$ (20,184)	$ (68,002)	$ (139,805)
Stock-based compensation	$ 30,923	33,245	$ 25,334
Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss		(68,002)
Stock-based compensation		33,245
As reported | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss		(66,427)
Stock-based compensation		31,670
Adjustment | Immaterial Error Correction, Consolidated Basis
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss		(1,575)
Stock-based compensation		$ 1,575

Discontinued operations - Narra

Discontinued operations - Narrative (Details) $ in Thousands			12 Months Ended
	Nov. 12, 2024 USD ($)	Apr. 17, 2024 USD ($) employee	Dec. 31, 2024 USD ($) reportable_segment
Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]			Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent
Number of reportable segments | reportable_segment			1
Outstanding minimum lease payments for the lease terminations			$ 2,300
Discontinued Operations, Disposed of by Sale | Global Cooling
Discontinued Operations [Line Items]
Cash required on closing date, funded by entity		$ 6,652
Repayment of indebtedness		2,600
Other liabilities		$ 2,643
Expected reduction of workforce | employee		47
Expected reduction of workforce (percent)		11%
Loss contingency accrual			4,000
Period of transition services		90 days
Restructuring costs		$ 3,471
Discontinued Operations, Disposed of by Sale | Global Cooling | Severance
Discontinued Operations [Line Items]
Restructuring costs		291
Discontinued Operations, Disposed of by Sale | Global Cooling | Stock Compensation
Discontinued Operations [Line Items]
Restructuring costs		3,180
Discontinued Operations, Disposed of by Sale | SciSafe
Discontinued Operations [Line Items]
Goodwill			11,300
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Severance
Discontinued Operations [Line Items]
Restructuring costs	$ 400
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Stock Compensation
Discontinued Operations [Line Items]
Restructuring costs	4,000
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Earn-Out Payment
Discontinued Operations [Line Items]
Restructuring costs	3,300
Discontinued Operations, Disposed of by Sale | CBS
Discontinued Operations [Line Items]
Goodwill			$ 1,100
Discontinued Operations, Disposed of by Sale | CBS | Stock Compensation
Discontinued Operations [Line Items]
Restructuring costs	$ 2,000
Global Cooling
Discontinued Operations [Line Items]
Cash required on closing date		$ 7,000

Discontinued operations - Loss

Discontinued operations - Loss on Disposal of Global Cooling (Details) - Discontinued Operations, Disposed of by Sale - Global Cooling $ / shares in Units, $ in Thousands	Apr. 17, 2024 USD ($) $ / shares
Discontinued Operations [Line Items]
Selling price: $1	$ 0
Selling price per share (in dollars per share) | $ / shares	$ 1
Cash to Global Cooling funded by Company	$ (6,652)
Costs to sell Global Cooling	(582)
Total proceeds	(7,234)
Less: SciSafe carrying basis as of November 12, 2024	(3,589)
Assumed liabilities: Accounts payable	2,643
Assumed liabilities: Debt	2,596
Less: Global Cooling carrying basis as of April 17, 2024	1,650
Less: Release of currency translation adjustment	(13)
Net gain (loss) on disposal	(8,897)
Accounts payable	500
Accrued expenses	$ 2,100

Discontinued operations - RIF a

Discontinued operations - RIF and Stock Compensation Expense Acceleration (Details) - Discontinued Operations, Disposed of by Sale - Global Cooling $ in Thousands	Apr. 17, 2024 USD ($)
Discontinued Operations [Line Items]
RIF employee costs	$ 1,546
Former Global Cooling employees	1,925
Restructuring costs	3,471
Severance
Discontinued Operations [Line Items]
RIF employee costs	291
Former Global Cooling employees	0
Restructuring costs	291
Stock Compensation
Discontinued Operations [Line Items]
RIF employee costs	1,255
Former Global Cooling employees	1,925
Restructuring costs	$ 3,180

Discontinued operations - Dives

Discontinued operations - Divestiture (Details) - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	Nov. 14, 2024	Nov. 12, 2024
SciSafe
Discontinued Operations [Line Items]
Cash proceeds received from Buyer		$ 71,291
Cash proceeds from escrow		483
Costs to sell		(506)
Total proceeds		71,268
Less: SciSafe carrying basis as of November 12, 2024		42,507
Less: Release of SciSafe currency translation adjustment		622
Net loss on disposal		28,139
Gross selling costs	$ 1,400	2,100
Additional selling costs	1,300	$ 1,600
CBS
Discontinued Operations [Line Items]
Cash proceeds received from Buyer	2,785
Cash proceeds from escrow	615
Net price adjustment	179
Costs to sell	(148)
Total proceeds	3,431
Less: CBS carrying basis as of November 14, 2024	6,796
Net loss on disposal	$ (3,365)

Discontinued operations - Asset

Discontinued operations - Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Discontinued Operations [Line Items]
Total current assets, discontinued operations	$ 0	$ 36,691
Total current liabilities, discontinued operations	0	18,816
Deferred tax liabilities	$ 0	74
Discontinued Operations, Disposed of by Sale
Discontinued Operations [Line Items]
Cash and cash equivalents		7,532
Restricted cash		10
Accounts receivable, net		10,758
Inventories		16,292
Prepaid expenses and other current assets		2,099
Total current assets, discontinued operations		36,691
Assets held for rent, net		796
Property and equipment, net		15,387
Operating lease right-of-use assets, net		4,568
Financing lease right-of-use assets, net		94
Long-term deposits and other assets		203
Intangible assets, net		9,153
Goodwill		12,437
Total assets, discontinued operations		79,329
Accounts payable		4,671
Accrued expenses and other current liabilities		3,029
Sales taxes payable		1,043
Warranty liability		7,638
Lease liabilities, operating, current portion		1,512
Lease liabilities, financing, current portion		376
Debt, current portion		547
Total current liabilities, discontinued operations		18,816
Lease liabilities, operating, long-term		4,510
Lease liabilities, financing, long-term		1,168
Debt, long-term		751
Deferred tax liabilities		74
Total liabilities, discontinued operations		25,319
Discontinued Operations, Disposed of by Sale | Global Cooling
Discontinued Operations [Line Items]
Cash and cash equivalents		2,090
Restricted cash		0
Accounts receivable, net		1,728
Inventories		11,248
Prepaid expenses and other current assets		303
Total current assets, discontinued operations		15,369
Assets held for rent, net		0
Property and equipment, net		146
Operating lease right-of-use assets, net		0
Financing lease right-of-use assets, net		0
Long-term deposits and other assets		4
Intangible assets, net		0
Goodwill		0
Total assets, discontinued operations		15,519
Accounts payable		3,367
Accrued expenses and other current liabilities		1,156
Sales taxes payable		481
Warranty liability		7,507
Lease liabilities, operating, current portion		263
Lease liabilities, financing, current portion		22
Debt, current portion		0
Total current liabilities, discontinued operations		12,796
Lease liabilities, operating, long-term		1,016
Lease liabilities, financing, long-term		11
Debt, long-term		0
Deferred tax liabilities		0
Total liabilities, discontinued operations		13,823
Discontinued Operations, Disposed of by Sale | SciSafe
Discontinued Operations [Line Items]
Cash and cash equivalents		5,102
Restricted cash		0
Accounts receivable, net		6,353
Inventories		0
Prepaid expenses and other current assets		895
Total current assets, discontinued operations		12,350
Assets held for rent, net		796
Property and equipment, net		15,241
Operating lease right-of-use assets, net		4,568
Financing lease right-of-use assets, net		94
Long-term deposits and other assets		199
Intangible assets, net		9,153
Goodwill		11,333
Total assets, discontinued operations		53,734
Accounts payable		578
Accrued expenses and other current liabilities		1,300
Sales taxes payable		44
Warranty liability		0
Lease liabilities, operating, current portion		1,249
Lease liabilities, financing, current portion		74
Debt, current portion		447
Total current liabilities, discontinued operations		3,692
Lease liabilities, operating, long-term		3,494
Lease liabilities, financing, long-term		27
Debt, long-term		679
Deferred tax liabilities		0
Total liabilities, discontinued operations		7,892
Discontinued Operations, Disposed of by Sale | CBS
Discontinued Operations [Line Items]
Cash and cash equivalents		340
Restricted cash		10
Accounts receivable, net		2,677
Inventories		5,044
Prepaid expenses and other current assets		901
Total current assets, discontinued operations		8,972
Assets held for rent, net		0
Property and equipment, net		0
Operating lease right-of-use assets, net		0
Financing lease right-of-use assets, net		0
Long-term deposits and other assets		0
Intangible assets, net		0
Goodwill		1,104
Total assets, discontinued operations		10,076
Accounts payable		726
Accrued expenses and other current liabilities		573
Sales taxes payable		518
Warranty liability		131
Lease liabilities, operating, current portion		0
Lease liabilities, financing, current portion		280
Debt, current portion		100
Total current liabilities, discontinued operations		2,328
Lease liabilities, operating, long-term		0
Lease liabilities, financing, long-term		1,130
Debt, long-term		72
Deferred tax liabilities		74
Total liabilities, discontinued operations		$ 3,604

Discontinued operations - Compo

Discontinued operations - Components of Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Discontinued Operations [Line Items]
(Loss) income before income taxes	$ (8,665)	$ (49,362)	$ (139,979)
Income tax expense	(132)	(193)	(214)
Loss from discontinued operations	(8,797)	(49,555)	(140,193)
Discontinued Operations, Disposed of by Sale
Discontinued Operations [Line Items]
Revenue	37,738	67,416	85,519
Cost of revenue	(35,346)	(66,597)	(78,609)
Operating expenses	(25,852)	(32,631)	(30,456)
Intangible asset impairment charges		(15,485)	(110,364)
Intangible asset amortization	(764)	(1,661)	(5,706)
Other expense, net	(318)	(404)	(363)
(Loss) gain on disposal	15,877
(Loss) income before income taxes	(8,665)	(49,362)	(139,979)
Income tax expense	(132)	(193)	(214)
Loss from discontinued operations	(8,797)	(49,555)	(140,193)
Discontinued Operations, Disposed of by Sale | Global Cooling
Discontinued Operations [Line Items]
Revenue	7,157	35,826	47,915
Cost of revenue	(8,389)	(36,682)	(51,621)
Operating expenses	(9,418)	(20,162)	(19,211)
Intangible asset impairment charges		(7,175)	(110,364)
Intangible asset amortization	0	(131)	(3,969)
Other expense, net	(25)	(90)	(255)
(Loss) gain on disposal	(8,897)
(Loss) income before income taxes	(19,572)	(28,414)	(137,505)
Income tax expense	(10)	(4)	(14)
Loss from discontinued operations	(19,582)	(28,418)	(137,519)
Discontinued Operations, Disposed of by Sale | SciSafe
Discontinued Operations [Line Items]
Revenue	18,440	18,014	21,462
Cost of revenue	(16,357)	(17,283)	(15,060)
Operating expenses	(11,467)	(5,316)	(5,697)
Intangible asset impairment charges		0	0
Intangible asset amortization	(764)	(907)	(907)
Other expense, net	(183)	(100)	(84)
(Loss) gain on disposal	28,139
(Loss) income before income taxes	17,808	(5,592)	(286)
Income tax expense	(122)	(180)	(191)
Loss from discontinued operations	17,686	(5,772)	(477)
Discontinued Operations, Disposed of by Sale | CBS
Discontinued Operations [Line Items]
Revenue	12,141	13,576	16,142
Cost of revenue	(10,600)	(12,632)	(11,928)
Operating expenses	(4,967)	(7,153)	(5,548)
Intangible asset impairment charges		(8,310)	0
Intangible asset amortization	0	(623)	(830)
Other expense, net	(110)	(214)	(24)
(Loss) gain on disposal	(3,365)
(Loss) income before income taxes	(6,901)	(15,356)	(2,188)
Income tax expense	0	(9)	(9)
Loss from discontinued operations	$ (6,901)	$ (15,365)	$ (2,197)

Discontinued operations - Nonca

Discontinued operations - Noncash Related Costs For Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Discontinued Operations [Line Items]
Depreciation	$ 2,406	$ 3,504	$ 3,185
Amortization	764	1,661	5,706
Stock-based compensation	14,391	9,996	7,608
Interest expense, net	206	363	403
Capital expenditures	2,920	5,409	7,602
Global Cooling
Discontinued Operations [Line Items]
Depreciation	0	397	616
Amortization	0	131	3,969
Stock-based compensation	4,191	4,734	3,304
Interest expense, net	42	131	257
Capital expenditures	0	0	0
SciSafe
Discontinued Operations [Line Items]
Depreciation	2,402	2,636	2,081
Amortization	764	907	907
Stock-based compensation	6,410	2,759	2,465
Interest expense, net	50	13	118
Capital expenditures	2,200	4,659	6,790
CBS
Discontinued Operations [Line Items]
Depreciation	4	471	488
Amortization	0	623	830
Stock-based compensation	3,790	2,503	1,839
Interest expense, net	114	219	28
Capital expenditures	$ 720	$ 750	$ 812

Fair value measurement - Schedu

Fair value measurement - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	$ 13,826	$ 16,836
Fair Value, Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets	102,945	41,870
Fair Value, Recurring | U.S. government securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	1,494	5,170
Fair Value, Recurring | Corporate debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	9,000	9,674
Fair Value, Recurring | Other debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	3,332	1,992
Fair Value, Recurring | Money market accounts
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents	89,119	25,034
Fair Value, Recurring | Level 1
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets	91,011	30,204
Fair Value, Recurring | Level 1 | U.S. government securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	1,494	5,170
Fair Value, Recurring | Level 1 | Corporate debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	398	0
Fair Value, Recurring | Level 1 | Other debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 1 | Money market accounts
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents	89,119	25,034
Fair Value, Recurring | Level 2
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets	11,934	11,666
Fair Value, Recurring | Level 2 | U.S. government securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 2 | Corporate debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	8,602	9,674
Fair Value, Recurring | Level 2 | Other debt securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Available-for-sale securities	3,332	1,992
Fair Value, Recurring | Level 2 | Money market accounts
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents	$ 0	$ 0

Fair value measurement - Sche_2

Fair value measurement - Schedule of the Changes in Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 4,456
Change in fair value recognized in net loss from continuing operations	(2,193)
Payment of contingent consideration earned	(2,263)
Ending balance	$ 0

Investments - Schedule of Avail

Investments - Schedule of Available-For-Sale Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, current portion	$ 9,180	$ 16,285
Gross unrealized Gains, current portion	19	7
Gross unrealized Losses, current portion	(1)	(4)
Available-for-sale securities, current portion	9,198	16,288
Available-for-sale securities, long term	4,628	548
Total	13,802	16,830
Total available-for-sale securities, Gross unrealized Gains	28	10
Total available-for-sale securities, Gross unrealized Losses	(4)	(4)
Total available-for-sale securities, Estimated Fair Value	13,826	16,836
Amortized Cost
Due in one year or less	9,180
Due after one year through five years	4,622
Total	13,802	16,830
Estimated Fair Value
Due in one year or less	9,198
Due after one year through five years	4,628
Total	13,826	16,836
U.S. government securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, current portion	1,493	5,169
Gross unrealized Gains, current portion	1	1
Gross unrealized Losses, current portion	0	0
Available-for-sale securities, current portion	1,494	5,170
Corporate debt securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, current portion	5,775	9,673
Gross unrealized Gains, current portion	14	5
Gross unrealized Losses, current portion	(1)	(4)
Available-for-sale securities, current portion	5,788	9,674
Amortized Cost, Available-for-sale securities, long-term	3,210
Gross unrealized Gains, Available-for-sale securities, long-term	4
Gross unrealized Losses, Available-for-sale securities, long-term	(2)
Available-for-sale securities, long term	3,212
Other debt securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, current portion	1,912	1,443
Gross unrealized Gains, current portion	4	1
Gross unrealized Losses, current portion	0	0
Available-for-sale securities, current portion	1,916	1,444
Amortized Cost, Available-for-sale securities, long-term	1,412	545
Gross unrealized Gains, Available-for-sale securities, long-term	5	3
Gross unrealized Losses, Available-for-sale securities, long-term	(1)	0
Available-for-sale securities, long term	$ 1,416	$ 548

Investments - Schedule of Debt

Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Fair value, less than 12 months	$ 3,121	$ 6,777
Unrealized losses, less than 12 months	(4)	(5)
Total fair value	3,121	6,777
Total unrealized Losses	(4)	(5)
Corporate debt securities
Debt Securities, Available-for-Sale [Line Items]
Fair value, less than 12 months	2,091	5,871
Unrealized losses, less than 12 months	(3)	(4)
Total fair value	2,091	5,871
Total unrealized Losses	(3)	(4)
Other debt securities
Debt Securities, Available-for-Sale [Line Items]
Fair value, less than 12 months	1,030	906
Unrealized losses, less than 12 months	(1)	(1)
Total fair value	1,030	906
Total unrealized Losses	$ (1)	$ (1)

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
iVexSol, Inc.
Debt Securities, Available-for-Sale [Line Items]
Fair value of non-marketable equity securities without readily determinable fair value			$ 4,100	$ 4,100
Series E Preferred Stock | PanTHERA CryoSolutions, Inc.
Debt Securities, Available-for-Sale [Line Items]
Fair value of non-marketable equity securities without readily determinable fair value		$ 1,000	1,000
Series A-1 and A-2, Preferred Stock | iVexSol, Inc.
Debt Securities, Available-for-Sale [Line Items]
Fair value of non-marketable equity securities without readily determinable fair value			$ 4,100
Impairment charge	$ 4,100

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 11,768	$ 14,668
Work in progress	4,082	3,475
Finished goods	13,163	9,021
Total	$ 29,013	$ 27,164

Inventories - Narrative (Detail

Inventories - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Inventory Disclosure [Abstract]
Inventory write-down	$ 3.4

Leases - Narrative (Details)

Leases - Narrative (Details) - Real Estate Lease	Dec. 31, 2024
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	4 years
Operating lease, remaining lease term	1 year
Operating lease, renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	11 years
Operating lease, remaining lease term	7 years
Operating lease, renewal term	5 years

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted average discount rate - operating leases	6.40%	4.50%
Weighted average remaining lease term in years - operating leases	6 years 1 month 6 days	7 years 1 month 6 days

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease costs	$ 1,997	$ 1,630	$ 1,560
Short-term lease costs	59	260	280
Total operating lease costs	2,056	1,890	1,840
Variable lease costs	1,103	797	677
Total lease expense	$ 3,159	$ 2,687	$ 2,517

Leases - Schedule of Maturities

Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating Leases
2025	$ 2,351
2026	3,029
2027	2,583
2028	2,642
2029	2,724
Thereafter	3,946
Total lease payments	17,275
Less: interest	(3,041)
Total present value of lease liabilities	$ 14,234

Assets held for rent - Schedule

Assets held for rent - Schedule of Assets Held for Rent (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Shippers placed in service	$ 9,505	$ 9,866
Accumulated depreciation	(6,499)	(5,600)
Net	3,006	4,266
Shippers and related components in production	3,097	2,651
Total	$ 6,103	$ 6,917

Assets held for rent - Narrativ

Assets held for rent - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Assets held for rent, depreciation expense	$ 2.1	$ 2.9	$ 2.8

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Subtotal	$ 10,384	$ 9,952
Less: Accumulated depreciation	(4,300)	(4,263)
Property and equipment, net	6,084	5,689
Leasehold improvements
Property, Plant and Equipment [Line Items]
Subtotal	3,527	3,503
Furniture and computer equipment
Property, Plant and Equipment [Line Items]
Subtotal	306	596
Manufacturing and other equipment
Property, Plant and Equipment [Line Items]
Subtotal	4,073	3,340
Construction in-progress
Property, Plant and Equipment [Line Items]
Subtotal	$ 2,478	$ 2,513

Property and equipment - Narrat

Property and equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, depreciation expense	$ 0.7	$ 0.8	$ 0.8

Accrued expenses and other cu_3

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Accrued expenses	$ 7,116	$ 6,620
Accrued taxes	0	264
Accrued compensation	5,232	2,196
Deferred revenue, current	103	41
Total accrued expenses and other current liabilities	$ 12,451	$ 9,121

Goodwill and intangible asset_2

Goodwill and intangible assets - Schedule of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 212,304
Ending balance	212,304
SciSafe Holdings, Inc
Goodwill [Roll Forward]
Goodwill allocated in divestiture	(11,333)
CBS
Goodwill [Roll Forward]
Goodwill allocated in divestiture	(1,104)
Immaterial Error Correction, Consolidated Basis
Goodwill [Roll Forward]
Beginning balance	$ 224,741

Goodwill and intangible asset_3

Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (15,833)	$ (13,096)
Total	9,559
Intangible assets, gross	25,392	25,092
Intangible assets, net	$ 9,559	$ 11,996
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	3 years 3 months 18 days	4 years 3 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 2,516	$ 2,516
Accumulated Amortization	(2,508)	(2,495)
Total	$ 8	$ 21
Customer relationships | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	7 months 6 days	1 year 7 months 6 days
Tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 4,114	$ 4,114
Accumulated Amortization	(1,799)	(1,389)
Total	$ 2,315	$ 2,725
Tradenames | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	5 years 10 months 24 days	6 years 10 months 24 days
Technology - acquired
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 18,672	$ 18,372
Accumulated Amortization	(11,436)	(9,122)
Total	$ 7,236	$ 9,250
Technology - acquired | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	3 years 1 month 6 days	4 years 1 month 6 days
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 90	$ 90
Accumulated Amortization	(90)	(90)
Total	$ 0	$ 0
Non-compete agreements | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	0 years	0 years

Goodwill and intangible asset_4

Goodwill and intangible assets - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization	$ 2,737	$ 3,520	$ 3,990

Goodwill and intangible asset_5

Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 2,807
2026	2,692
2027	1,938
2028	828
2029	530
Thereafter	764
Total	$ 9,559

Commitments and contingencies (

Commitments and contingencies (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($)	Dec. 31, 2024 USD ($) lawsuit shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Jun. 05, 2023 shares	May 03, 2021 shares
Other Commitments [Line Items]
Number of pending litigation claims | lawsuit		1
Sales and excise tax payable | $		$ 4,300	$ 4,400
Common stock, shares issued (in shares)		46,906,765	45,167,225
Common stock, shares outstanding (in shares)		46,906,765	45,167,225
Gain on settlement of Global Cooling escrow | $	$ 5,100	$ 0	$ 5,115	$ 0
GCI Escrow
Other Commitments [Line Items]
Common stock, shares issued (in shares)						6,646,870
GCI Escrow | Escrow Shares
Other Commitments [Line Items]
Shares deposited into escrow, percent						9%
Shares deposited into escrow, holding term						18 months
GCI Escrow | General Escrow Shares
Other Commitments [Line Items]
Shares deposited into escrow, percent						5%
GCI Escrow | General Escrow Shares | Settled Litigation
Other Commitments [Line Items]
Shares deposited into escrow, percent					65%
Common stock, shares outstanding (in shares)					216,024

Long-term debt - Narrative (Det

Long-term debt - Narrative (Details) - USD ($) $ in Thousands	Sep. 20, 2022	Dec. 31, 2024	Nov. 11, 2024	Apr. 17, 2024
The 2023 Term Loan
Debt Instrument [Line Items]
Term loan agreement	$ 60,000
Agreement provides for borrowings	30,000
Options to borrow	10,000
Milestone achievements	10,000
Discretion of lender	10,000
Proceeds from debt	$ 20,000
Debt instrument, variable interest rate, type [extensible enumeration]	Prime Rate [Member]
Interest at a floating rate	0.50%
Interest rate, maximum stated percentage for each tranche borrowed	1%
Debt instrument, balloon payment due	$ 1,000
Interest rate		8.90%
Debt instrument, face amount		$ 15,900
Second Amendment Term Loan
Debt Instrument [Line Items]
Termination fee, amount			$ 750	$ 500

Long-term debt - Schedule of De

Long-term debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs	$ 15,975	$ 23,944
Less: unamortized debt issuance costs	(35)	(98)
Total	15,940	23,846
Less: current portion of debt	(10,943)	(6,285)
Debt, long-term	$ 4,997	$ 17,561
Global Cooling Term Notes
Debt Instrument [Line Items]
Interest Rate	4%	4%
Total debt, excluding unamortized debt issuance costs	$ 0	$ 2,596
Term Loan
Debt Instrument [Line Items]
Interest Rate	7%	7%
Total debt, excluding unamortized debt issuance costs	$ 15,000	$ 20,000
Insurance premium financing
Debt Instrument [Line Items]
Interest Rate	8.30%	8.30%
Total debt, excluding unamortized debt issuance costs	$ 975	$ 1,348
Total long-term debt
Debt Instrument [Line Items]
Debt, long-term	$ 4,997	$ 17,561

Long-term debt - Schedule of Ma

Long-term debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
2025	$ 10,943
2026	4,997
2027	0
2028	0
2029	0
Thereafter	0
Total	$ 15,940	$ 23,846

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details) $ / shares in Units, $ in Thousands						3 Months Ended	12 Months Ended
	Mar. 08, 2024 USD ($) peer $ / shares shares	Oct. 19, 2023 USD ($) shares	Jan. 03, 2023 USD ($) peer shares	Feb. 24, 2022 USD ($) peer shares	Feb. 08, 2021 shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Jul. 21, 2023 shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jul. 31, 2020 shares	May 31, 2017 shares	Dec. 31, 2013 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)							4 years
Weighted Average Remaining Contractual Life							1 year 5 months 12 days
Share-based payment arrangement, expense | $							$ 16,514	$ 23,249	$ 17,726
Number of peers | peer	20		20	20
Service vesting-based restricted stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested restricted stock awards (in shares)						1,295,640	1,295,640	2,312,898	1,879,215
Aggregate fair value of the service vesting-based awards granted | $							$ 10,000	$ 25,000	$ 34,700
Aggregate fair value of the service vesting-based awards that vested | $							$ 27,700	$ 20,500	12,600
Grants in period (in shares)							484,886	1,907,101
Share-based payment arrangement, expense | $							$ 10,800	$ 15,700	$ 13,600
Unrecognized compensation costs for service vesting-based stock options | $						$ 18,000	$ 18,000
Period for recognition							2 years 7 months 6 days
Grant date fair value (in dollars per share) | $ / shares						$ 16	$ 16	$ 18.32	$ 28.94
Vesting to current employees (in shares)							1,323,729	1,237,221
Service vesting-based restricted stock | Executive Officer | Share-Based Payment Arrangement, Tranche One
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting percentage									25%
Service vesting-based restricted stock | Executive Officer | Share-Based Payment Arrangement, Tranche Two
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting percentage									25%
Service vesting-based restricted stock | Executive Officer | Share-Based Payment Arrangement, Tranche Three
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting percentage									25%
Service vesting-based restricted stock | Executive Officer | Share-Based Payment Arrangement, Tranche Four
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting percentage									25%
Service vesting-based stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, outstanding (in shares)						127,000	127,000	217,250	456,293
Aggregate intrinsic value of outstanding service vesting-based stock options | $						$ 3,000	$ 3,000
Aggregate intrinsic value of exercisable service vesting-based stock options | $						$ 3,000	3,000
Intrinsic value of service vesting-based awards exercised | $							$ 1,800	$ 3,900	$ 4,100
Service based-vesting options granted (in shares)							0	0	0
Weighted Average Remaining Contractual Life							1 year 4 months 24 days
Market-based restricted stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested restricted stock awards (in shares)		150,155				495,686	495,686	509,166	271,044
Grants in period (in shares)	300,529		30,616				312,081	268,738
Share-based payment arrangement, expense | $		$ 1,700					$ 4,500	$ 6,500	$ 4,300
Unrecognized compensation costs for service vesting-based stock options | $						$ 3,300	$ 3,300
Period for recognition							1 year
Total shareholder return attainment	125%		100%
Grant date fair value (in dollars per share) | $ / shares						$ 25.69	$ 25.69	$ 26.50	$ 30.64
Performance-based awards granted | $							$ 6,300	$ 6,500	$ 6,700
Vesting to current employees (in shares)							325,561	30,616
Historical volatility	80%		78%
Dividend yield	0%		0%	0%
Risk-free interest rate	4.60%		4.40%
Measurement date with a maturity period	2 years		2 years	2 years
Aggregate fair value of the performance-based awards | $							$ 5,700	$ 700	$ 5,000
Market-based restricted stock | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shareholder return attainment	0%		0%	0%
Market-based restricted stock | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shareholder return attainment	200%		200%	200%
Market-based restricted stock | Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate fair value of the service vesting-based awards granted | $			$ 1,300
Grants in period (in shares)	239,464		268,738	240,428	30,616
Share-based payment arrangement, expense | $	$ 6,300		$ 6,800	$ 6,700
Market-based restricted stock | Michael Rice | Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grants in period (in shares)			99,038	70,094
Performance-based stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Service based-vesting options granted (in shares)								0	0
Grants in period (in shares)	109,512
Share-based payment arrangement, expense | $						$ 400	1,200
Unrecognized compensation costs for service vesting-based stock options | $						$ 1,500	$ 1,500
Period for recognition							1 year
Grant date fair value (in dollars per share) | $ / shares	$ 17.36
Shares granted percentage						100%
Performance-based awards granted | $							$ 1,900
Vesting to current employees (in shares)							0
Performance-based stock options | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shareholder return attainment	0%
Performance-based stock options | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shareholder return attainment	200%
Market-based Restricted Stock Second Issuance
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Historical volatility			68%	63%
Dividend yield			0%	0%
Risk-free interest rate			0.10%	1.50%
The 2013 Performance Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)											8,500,000	6,500,000	5,000,000	4,100,000	3,100,000
Options, outstanding (in shares)						127,000	127,000
Unvested restricted stock awards (in shares)						500,000	500,000
The 2023 Performance Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)										4,200,000
The 2023 Performance Incentive Plan | Service vesting-based restricted stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested restricted stock awards (in shares)						1,400,000	1,400,000

Stock-based compensation - Sche

Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Wtd. Avg. Exercise Price
Outstanding as of end of period (in dollars per share)	$ 2.19
Service vesting-based stock options
Shares
Outstanding as of beginning of period (in shares)	217,250	456,293
Exercised (in shares)	(90,250)	(239,043)
Outstanding at end of year (in shares)	127,000	217,250
Stock options exercisable at year end (in shares)	127,000	217,250
Wtd. Avg. Exercise Price
Outstanding as of beginning of period (in dollars per share)	$ 2.21	$ 2.17
Exercised (in dollars per share)	2.23	2.12
Outstanding as of end of period (in dollars per share)	2.19	2.21
Stock options exercisable at year end (in dollars per share)	$ 2.19	$ 2.21

Stock-based compensation - Sc_2

Stock-based compensation - Schedule of Share-Based Payment Arrangement, Option, Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares) | shares	127,000
Weighted Average Remaining Contractual Life	1 year 5 months 12 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.19
$1.00 - 1.50
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares) | shares	2,000
Weighted Average Remaining Contractual Life	1 year 10 months 6 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 1.49
$1.51 - 2.00
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares) | shares	115,000
Weighted Average Remaining Contractual Life	1 year 3 months 25 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 1.89
$2.51 - 8.60
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares) | shares	10,000
Weighted Average Remaining Contractual Life	2 years 11 months 1 day
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 5.69

Stock-based compensation - Sc_3

Stock-based compensation - Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - $ / shares			12 Months Ended
	Mar. 08, 2024	Jan. 03, 2023	Dec. 31, 2024	Dec. 31, 2023
Service vesting-based restricted stock
Shares
Outstanding as of beginning of period (in shares)			2,312,898	1,879,215
Granted (in shares)			484,886	1,907,101
Vested (in shares)			(1,323,729)	(1,237,221)
Forfeited (in shares)			(178,415)	(236,197)
Outstanding as of end of period (in shares)			1,295,640	2,312,898
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period (in dollars per share)			$ 18.32	$ 28.94
Granted (in dollars per share)			20.65	13.12
Vested (in dollars per share)			21.57	24.97
Forfeited (in dollars per share)			17.09	25.88
Outstanding as of end of period (in dollars per share)			$ 16	$ 18.32
Market-based restricted stock
Shares
Outstanding as of beginning of period (in shares)			509,166	271,044
Granted (in shares)	300,529	30,616	312,081	268,738
Vested (in shares)			(325,561)	(30,616)
Outstanding as of end of period (in shares)			495,686	509,166
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period (in dollars per share)			$ 26.50	$ 30.64
Granted (in dollars per share)			26.61	25.19
Vested (in dollars per share)			27.84	51.65
Outstanding as of end of period (in dollars per share)			$ 25.69	$ 26.50

Stock-based compensation - Sc_4

Stock-based compensation - Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 16,514	$ 23,249	$ 17,726
Research and development costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	2,273	4,665	2,423
Sales and marketing costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	1,765	3,615	2,456
General and administrative costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	10,864	13,447	11,524
Cost of revenue
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 1,612	$ 1,522	$ 1,323

Income taxes - Schedule of Comp

Income taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Deferred:
Total deferred tax provision	$ 64	$ 62	$ 5,238
Income tax benefit	38	24	5,236
Continuing Operations
Current:
State	(26)	(46)	(11)
Total current tax provision	(26)	(46)	(11)
Deferred:
Federal	64	70	2,929
State	0	0	2,318
Total deferred tax provision	64	70	5,247
Income tax benefit	$ 38	$ 24	$ 5,236

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Stock-based compensation, tax benefits	$ 300,000	$ 0	$ 0
Operating loss carryforwards	165,200,000
Deferred tax assets, operating loss carryforwards	38,700,000
Deferred tax assets, operating loss carryforwards, not subject to expiration	$ 126,500,000

Income taxes - Schedule of Effe

Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory tax	21%	21%	21%
State tax, net of federal benefit	6%	4%	11%
Stock compensation	4%	(5.00%)	0%
Sec. 162(m) limitation on executive compensation	(4.00%)	(6.00%)	(30.00%)
Fair value change in contingent consideration	0%	2%	21%
Tax credits	4%	4%	17%
Change in valuation allowance	(27.00%)	(24.00%)	74%
Gain on escrow settlement	0	0.05	0
Other	(4.00%)	(1.00%)	(6.00%)
Total	0%	0%	108%

Income taxes - Schedule of Defe

Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets related to:
Net operating loss carryforwards	$ 39,079	$ 35,505
Capital loss carryforward	7,011	0
Tax credit carryforward	2,695	2,226
Stock-based compensation	2,141	3,008
Accruals and reserves	1,883	3,590
Inventory	1,410	1,408
Fixed assets	568	585
Lease liabilities	3,540	3,950
Capitalized research and development	3,222	4,818
Fair value change in investments	556	0
Other	1,084	875
Total deferred tax assets	63,189	55,965
Deferred tax liabilities related to:
Intangibles	(2,326)	(3,696)
Right-of-use assets	(2,654)	(2,500)
Fair value change in investments	0	(440)
Total deferred tax liabilities	(4,980)	(6,636)
Net deferred tax assets before valuation allowance	58,209	49,329
Less: valuation allowance	58,333	49,517	$ 33,402	$ 2,993
Net deferred tax liabilities	(124)	(188)
Less: deferred tax liability, discontinued operations	0	(74)
Net deferred tax liabilities, continuing operations	$ (124)	$ (114)

Income taxes - Schedule of Valu

Income taxes - Schedule of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Beginning balance	$ 49,517	$ 33,402	$ 2,993
Net deferred tax assets divested	(7,173)	0	0
Charged to income tax expense	15,989	16,115	30,409
Ending balance	$ 58,333	$ 49,517	$ 33,402

Income taxes - Schedule of Unre

Income taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 954	$ 610
Increase related to prior year tax positions	0	20
Increase related to current year tax positions	201	324
Ending balance	$ 1,155	$ 954

Segment, customer, and geogra_3

Segment, customer, and geographic information - Schedules of Concentration of Risk, by Risk Factor (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Customer A | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	18%
Customer A | Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	15%	14%	18%
Customer B | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	21%	13%
Customer B | Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	13%	11%	14%

Segment, customer, and geogra_4

Segment, customer, and geographic information - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) reportable_segment reporting_unit	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Number of reportable segments | reportable_segment	1
Number of reportable units | reporting_unit	1
United States
Segment Reporting Information [Line Items]
Long-lived assets | $	$ 22.9
Purchases | Supplier Concentration Risk | One Supplier
Segment Reporting Information [Line Items]
Concentration risk, percentage		20%	16%
Accounts Payable | Supplier Concentration Risk | One Supplier
Segment Reporting Information [Line Items]
Concentration risk, percentage		17%

Segment, customer, and geogra_5

Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
CryoStor | Revenue | Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk, percentage	73%	73%	77%

Segment, customer, and geogra_6

Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details) - Revenue - Geographic Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Concentration risk, percentage	100%	100%	100%
United States
Segment Reporting Information [Line Items]
Concentration risk, percentage	75%	82%	82%
Europe, Middle East, Africa (EMEA)
Segment Reporting Information [Line Items]
Concentration risk, percentage	19%	12%	12%
Other
Segment Reporting Information [Line Items]
Concentration risk, percentage	6%	6%	6%

Employee benefit plan (Details)

Employee benefit plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Defined contribution plan, employer matching contribution, percent of employees' gross pay	100%
Defined contribution plan, employer discretionary contribution amount	$ 0.6	$ 0.5	$ 0.4